[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 112
1. Venizelos I, Tamiolakis D, Petrakis G: Primary combined carcinoid and adenocarcinoma of the ileum associated with transitional carcinoma of the bladder. Single case report. Rev Esp Enferm Dig; 2007 Mar;99(3):145-8
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary combined carcinoid and adenocarcinoma of the ileum associated with transitional carcinoma of the bladder. Single case report.
  • Composite neoplasms, carcinoid and adenocarcinoma have been reported to occur in several parts of the body, including the stomach, ampulla of Vater, large bowel, lung, and urinary bladder.
  • Here we report a case of a 74-year-old male with a composite carcinoid-adenocarcinoma of the ileum associated with a transitional cell carcinoma of the bladder.
  • The microscopical examination of the composite tumor showed an admixture of typical carcinoid tumor and moderately a differentiated adenocarcinoma.
  • A review of the literature revealed that this is the first reported case of composite carcinoid-adenocarcinoma of the ileum associated with transitional cell carcinoma of the urinary bladder.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoid Tumor / pathology. Carcinoma, Transitional Cell / pathology. Ileal Neoplasms / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rev Esp Enferm Dig. 2007 Nov;99(11):682. Venizelos, I D [corrected to Venizelos, I]; Lambropoulou, M [removed]; Constantinidis, T [removed]; Alexiadis, G [removed]; Papadopoulos, N [removed]
  • (PMID = 17516827.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Maletic V, Cerovic S, Lazic M, Stojanovic M, Stevanovic P: Synchronous and multiple transitional cell carcinoma of the bladder and urachal cyst. Int J Urol; 2008 Jun;15(6):554-6
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous and multiple transitional cell carcinoma of the bladder and urachal cyst.
  • Among urachal tumors, adenocarcinoma is most frequent, although other histological types can also be found.
  • The synchronous presentation of a urachal transitional cell tumor, along with recurrent superficial bladder tumors has not been reported previously.
  • We are reporting a 49-year-old male patient in whom transitional cell carcinoma of a urachal cyst was found with recurrent, multiple bladder tumors.
  • Most of the bladder tumors were resected transurethrally while open surgical excision of the urachal cyst with en bloc resection of the bladder dome was performed.
  • Recurrent bladder tumors were afterwards treated with Bacillus Calmette Guerin (BCG) instillations.
  • A year after surgery the patient has no signs of local recurrence or distant metastases of transitional cell carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / complications. Neoplasms, Multiple Primary / complications. Urachal Cyst / complications. Urinary Bladder Neoplasms / complications

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Urachal cyst.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489649.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


3. Basiri A, Ozhand A, Karami H, Parham HA, Safarinejad MR: The frequency of prostatic involvement in radical cystectomy specimens for transitional cell carcinoma of the bladder. J Pak Med Assoc; 2008 Sep;58(9):479-81
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The frequency of prostatic involvement in radical cystectomy specimens for transitional cell carcinoma of the bladder.
  • OBJECTIVE: To evaluate the frequency of prostatic involvement in pathologic samples of the patients who had undergone radical cystectomy due to transitional cell carcinoma (TCC) of the bladder.
  • MATERIALS: The files of the patients who had been subjected to radical cystectomy due to bladder TCC between 1998 and 2004 were evaluated retrospectively.
  • RESULTS: Of 147 patients, 36 (24/4%) had prostate TCC and 19 (12.9%) had prostate adenocarcinoma.
  • Two patients had both TCC and prostate adenocarcinoma.
  • Twenty-one cases had superficial bladder cancer (T1) and prostatic involvement was detected in TCC cases but in 9.5% of those with adenocarcinoma.
  • The prevalence of prostate adenocarcinoma in radical cystectomy samples (due to bladder TCC) is much lower in Iranian patients in comparison with the European and American patients (vs 12.9 and 17.5 to 45%, respectively).
  • CONCLUSION: Prostatic involvement by TCC had a direct relation with the stage (P = .01) and grade (P = .008) of the bladder tumour.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Cystectomy / methods. Prostate / pathology. Prostatic Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18846793.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


Advertisement
4. Komai Y, Kawakita M, Shimada O, Muguruma K, Sakaida N, Matsuda T: Colonic adenocarcinoma and stones in an Indiana pouch. Int J Urol; 2005 Apr;12(4):412-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic adenocarcinoma and stones in an Indiana pouch.
  • We report on a 63-year-old woman with adenocarcinoma and stones in an Indiana pouch.
  • Adenocarcinoma of an Indiana pouch is extremely rare.
  • To our knowledge, only four cases with adenocarcinoma in an Indiana pouch have been reported.
  • [MeSH-major] Adenocarcinoma / etiology. Colonic Neoplasms / etiology. Colonic Pouches / adverse effects. Urinary Calculi / etiology. Urinary Reservoirs, Continent / adverse effects
  • [MeSH-minor] Anastomosis, Surgical. Biopsy. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Colon / surgery. Colonoscopy. Fatal Outcome. Female. Follow-Up Studies. Humans. Middle Aged. Nephrectomy. Reoperation. Tomography, X-Ray Computed. Ureter / surgery. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948733.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


5. Hussein K, Nanda A, Al-Sabah H, Alsaleh QA: Sweet's syndrome (acute febrile neutrophilic dermatosis) associated with adenocarcinoma of prostate and transitional cell carcinoma of urinary bladder. J Eur Acad Dermatol Venereol; 2005 Sep;19(5):597-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sweet's syndrome (acute febrile neutrophilic dermatosis) associated with adenocarcinoma of prostate and transitional cell carcinoma of urinary bladder.
  • In the present report, we describe an 82-year-old male with SS in association with adenocarcinoma of the prostate and transitional cell carcinoma of the urinary bladder.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Transitional Cell / pathology. Neoplasms, Multiple Primary / diagnosis. Prostatic Neoplasms / pathology. Sweet Syndrome / diagnosis. Urinary Bladder Neoplasms / pathology


6. Zaghloul MS, Nouh A, Moneer M, El-Baradie M, Nazmy M, Younis A: Time-trend in epidemiological and pathological features of schistosoma-associated bladder cancer. J Egypt Natl Canc Inst; 2008 Jun;20(2):168-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time-trend in epidemiological and pathological features of schistosoma-associated bladder cancer.
  • OBJECTIVE: To investigate the different emerging trends in the features of bladder cancer along 17 years.
  • PATIENTS AND METHODS: During a 17-year period (1988- 2004), 5071 epithelial bladder cancer patients underwent radical cystectomy at the National Cancer Institute (NCI), Cairo University, Egypt.
  • RESULTS: There was a significant progressive increase in the patients' age with time and decrease in squamous/transitional ratio, with transient increase in male predominance during the 2nd time period.
  • Transitional cell carcinoma (TCC) patients were significantly older than those with squamous cell carcinoma (SCC) (p<0.001).
  • Progressive increase of age with time was evident in TCC, SCC and adenocarcinoma patients.
  • [MeSH-major] Adenocarcinoma / parasitology. Carcinoma, Squamous Cell / parasitology. Carcinoma, Transitional Cell / parasitology. Schistosomiasis / complications. Urinary Bladder Neoplasms / parasitology. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20029473.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


7. Koutsopoulos AV, Dambaki KI, Datseris G, Giannikaki E, Froudarakis M, Stathopoulos E: A novel combination of multiple primary carcinomas: urinary bladder transitional cell carcinoma, prostate adenocarcinoma and small cell lung carcinoma--report of a case and review of the literature. World J Surg Oncol; 2005 Jul 26;3:51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel combination of multiple primary carcinomas: urinary bladder transitional cell carcinoma, prostate adenocarcinoma and small cell lung carcinoma--report of a case and review of the literature.
  • CASE PRESENTATION: We report a case of a man in whom urinary bladder transitional cell carcinoma, metachronous prostate adenocarcinoma and small cell lung carcinoma were diagnosed within an eighteen-month period.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 1999 Jan;140(1):150-3 [10215787.001]
  • [Cites] J Cancer Res Clin Oncol. 1997;123(11-12):678-80 [9620229.001]
  • [Cites] Clin Exp Dermatol. 1999 Jul;24(4):281-2 [10457131.001]
  • [Cites] Eur J Dermatol. 1999 Sep;9(6):483-6 [10491509.001]
  • [Cites] Clin Exp Dermatol. 2000 Jul;25(5):381-3 [11012589.001]
  • [Cites] Oncol Rep. 2001 Jan-Feb;8(1):111-4 [11115580.001]
  • [Cites] Hinyokika Kiyo. 2003 May;49(5):261-4 [12822453.001]
  • [Cites] An Med Interna. 1992 May;9(5):257 [1324018.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1992 Aug 21;46(1):53-6 [1330760.001]
  • [Cites] Khirurgiia (Mosk). 1991 Oct;(10):136-43 [1803082.001]
  • [Cites] Am J Clin Oncol. 1991 Feb;14(1):49-51 [1987738.001]
  • [Cites] Eur J Surg Oncol. 1991 Feb;17(1):81-3 [1995363.001]
  • [Cites] Gut. 1979 May;20(5):414-9 [223949.001]
  • [Cites] Neurol Med Chir (Tokyo). 1986 Nov;26(11):908-12 [2437485.001]
  • [Cites] Gan No Rinsho. 1987 Nov;33(14):1846-53 [2826842.001]
  • [Cites] No Shinkei Geka. 1987 Sep;15(9):1011-7 [2827047.001]
  • [Cites] Gan No Rinsho. 1988 Jul;34(8):1001-5 [3043037.001]
  • [Cites] J Surg Oncol. 1986 May;32(1):8-10 [3724193.001]
  • [Cites] Cancer. 1985 Jun 1;55(11):2566-74 [3995473.001]
  • [Cites] Arch Otorhinolaryngol. 1985;242(1):7-12 [4038153.001]
  • [Cites] J Surg Oncol. 1985 Aug;29(4):261-3 [4079408.001]
  • [Cites] J Surg Oncol. 1979;11(1):75-8 [431085.001]
  • [Cites] Cancer. 1974 Apr;33(4):1134-44 [4406171.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 1979 Sep;96(9):619-21 [525951.001]
  • [Cites] IMJ Ill Med J. 1982 Feb;161(2):115-6 [6122671.001]
  • [Cites] Arch Pathol Lab Med. 1984 Apr;108(4):272-4 [6546663.001]
  • [Cites] Am J Med. 1983 Feb;74(2):343-8 [6572034.001]
  • [Cites] Arch Dermatol. 1980 Jun;116(6):687-9 [6892866.001]
  • [Cites] Pathol Int. 1994 Apr;44(4):325-32 [8044300.001]
  • [Cites] J Natl Med Assoc. 1994 May;86(5):387-8 [8046769.001]
  • [Cites] Cancer Lett. 1993 Sep 15;73(1):51-7 [8402598.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):452-5 [8425176.001]
  • [Cites] Cancer Res. 1993 Mar 1;53(5):957-61 [8439970.001]
  • [Cites] Dermatology. 1995;191(4):321-2 [8573931.001]
  • [Cites] Surg Neurol. 1996 Mar;45(3):219-29 [8638217.001]
  • [Cites] Jpn J Clin Oncol. 1996 Oct;26(5):368-73 [8895679.001]
  • [Cites] J Urol. 1997 Jan;157(1):65-7 [8976217.001]
  • [Cites] Pathol Int. 1997 Jan;47(1):68-72 [9051695.001]
  • [Cites] J Urol Nephrol (Paris). 1976 Jul-Aug;82(7-8):621-6 [1034027.001]
  • (PMID = 16045793.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1226150
  •  go-up   go-down


8. Lee SH, Chang PL, Chen SM, Sun GH, Chen CL, Shen BY, Wu YS, Tsui KH: Synchronous primary carcinomas of the bladder and prostate. Asian J Androl; 2006 May;8(3):357-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous primary carcinomas of the bladder and prostate.
  • AIM: To determine the incidence of adenocarcinoma of the prostate for patients undergoing radical cystoprostatectomy for bladder cancer in Taiwan.
  • METHODS: A total of 248 patients in Taiwan who were histologically confirmed for transitional cell carcinoma of the bladder underwent cystoprostatectomy.
  • This rate of incidentally found prostate cancer amongst our bladder cancer patients appeared to be lower than that found in bladder cancer patients in similar studies in USA.
  • CONCLUSION: Although the incidence of incidental prostate cancer in patients in Taiwan with bladder cancer is not high compared with that in Western countries, we suggest that digital rectal examination and prostate-specific antigen (PSA) are important screening tools for men with bladder cancer, especially for those aged 60 years and older in Taiwan.
  • [MeSH-major] Prostatic Neoplasms / complications. Urinary Bladder Neoplasms / complications
  • [MeSH-minor] Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Humans. Male. Neoplasm Staging. Prostatectomy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625287.001).
  • [ISSN] 1008-682X
  • [Journal-full-title] Asian journal of andrology
  • [ISO-abbreviation] Asian J. Androl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


9. Rogers CG, Palapattu GS, Shariat SF, Karakiewicz PI, Bastian PJ, Lotan Y, Gupta A, Vazina A, Gilad A, Sagalowsky AI, Lerner SP, Schoenberg MP: Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol; 2006 Jun;175(6):2048-53; discussion 2053
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder.
  • PURPOSE: The effect of bladder cancer histological subtypes other than transitional cell carcinoma (nonTCC) on clinical outcomes remains uncertain.
  • We conducted a multi-institutional retrospective study of patients with bladder cancer treated with radical cystectomy to assess the impact of nonTCC histology on bladder cancer specific outcomes.
  • MATERIALS AND METHODS: A total of 955 consecutive patients underwent radical cystectomy with bilateral pelvic lymphadenectomy for bladder cancer at 3 academic institutions.
  • NonTCC histology was present in 67 patients (7%), including squamous cell carcinoma in 26, adenocarcinoma in 13, small cell carcinoma in 10 and other nonTCC subtypes (ie spindle cell carcinoma, carcinosarcoma and undifferentiated carcinoma) in 18.
  • Bladder cancer specific progression and survival were assessed using Kaplan-Meier and multivariate Cox proportional hazards analyses.
  • RESULTS: Bladder cancer specific progression and mortality did not differ significantly between patients with SCC and TCC histologies.
  • Patients with nonTCC and nonSCC bladder cancer were at significantly increased risk for progression and death compared to patients with TCC or SCC (p <0.001).
  • In a multivariate analysis nonTCC and nonSCC histology was associated with an increased risk of bladder cancer progression and death (OR 2.272 and 2.585, respectively, p <0.001), even after adjusting for final pathological stage, lymph node status, lymphovascular invasion and neoadjuvant or adjuvant treatments.
  • CONCLUSIONS: NonTCC and nonSCC histological subtype is an independent predictor of bladder cancer progression and mortality in patients undergoing radical cystectomy for bladder cancer.
  • Patients with bladder TCC and SCC share similar stage specific clinical outcomes.
  • [MeSH-major] Carcinoma, Transitional Cell / mortality. Carcinoma, Transitional Cell / surgery. Cystectomy. Urinary Bladder Neoplasms / mortality. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2006 Jun;175(6):1987-8 [16697781.001]
  • (PMID = 16697800.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


10. De Santis M, Bachner M: New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder. Curr Opin Urol; 2007 Sep;17(5):363-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder.
  • PURPOSE OF REVIEW: To review the systemic treatment, patient selection and treatment outcome of transitional cell carcinoma of the urinary bladder, squamous cell carcinoma and adenocarcinoma, focusing on advances and findings within the last year.
  • RECENT FINDINGS: Cisplatin-based chemotherapy is considered to be the standard treatment for transitional cell carcinoma.
  • Only few data are available on the systemic treatment of squamous cell carcinoma and adenocarcinoma.
  • Complete resection seems to be more important than chemotherapy in the rare cases of adenocarcinoma of the urinary tract.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Transitional Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762632.001).
  • [ISSN] 0963-0643
  • [Journal-full-title] Current opinion in urology
  • [ISO-abbreviation] Curr Opin Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 58
  •  go-up   go-down


11. Hamano A, Udagawa K, Nomura S, Ishida T: Inguinal metastasis of a bladder mixed carcinoma with predominant adenocarcinoma component. Scand J Urol Nephrol; 2006;40(1):75-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inguinal metastasis of a bladder mixed carcinoma with predominant adenocarcinoma component.
  • We report a case of urinary bladder mixed carcinoma with inguinal metastasis.
  • Histological examination of the transurethral resection specimens revealed adenocarcinoma with small foci of squamous and transitional cell carcinomas.
  • [MeSH-major] Adenocarcinoma / secondary. Lymph Nodes / pathology. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Biopsy, Needle. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / secondary. Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Follow-Up Studies. Humans. Immunohistochemistry. Inguinal Canal. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452061.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


12. Ruoppolo M, Pezzica E, Milesi R, Corti D, Mercurio P, Fragapane G: [Neuroendocrine small-cell bladder cancer: our experience]. Urologia; 2010 Oct-Dec;77 Suppl 17:64-71
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroendocrine small-cell bladder cancer: our experience].
  • [Transliterated title] Carcinoma neuroendocrino a piccole cellule della vescica; nostra esperienza.
  • INTRODUCTION: Neuroendocrine bladder cancer is extremely rare, with an estimated incidence of 0.35-0.70% of all bladder tumors.
  • The small-cell carcinoma represents the most frequent histologic variant described.
  • Small-cell carcinoma is an epithelial tumor associated with a more aggressive behavior and poorer prognosis than transitional cell bladder carcinoma.
  • PATIENTS AND METHODS: We report three cases of pure neuroendocrine small-cell bladder cancer.
  • CONCLUSIONS: In the absence of a prospective study, and because of the rarity of the disease, the best treatment for small-cell bladder cancer remains uncertain.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Small Cell / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Fatal Outcome. Gastrointestinal Hemorrhage / etiology. Hematuria / etiology. Humans. Intestinal Neoplasms / complications. Intestinal Neoplasms / secondary. Leukemia, Lymphocytic, Chronic, B-Cell. Liver Neoplasms / secondary. Lymph Node Excision. Male. Middle Aged. Neoplasms, Second Primary. Peritoneal Neoplasms / secondary. Prostatic Neoplasms. Stomach Neoplasms. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308678.001).
  • [ISSN] 0391-5603
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


13. Gardner JM, Khurana H, Leach FS, Ayala AG, Zhai J, Ro JY: Adenocarcinoma in ectopic prostatic tissue at dome of bladder: a case report of a patient with urothelial carcinoma of the bladder and adenocarcinoma of the prostate. Arch Pathol Lab Med; 2010 Sep;134(9):1271-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in ectopic prostatic tissue at dome of bladder: a case report of a patient with urothelial carcinoma of the bladder and adenocarcinoma of the prostate.
  • We report a case of ectopic prostate tissue with an associated prostatic adenocarcinoma occurring in the dome of the urinary bladder.
  • Cystoscopic examination revealed a sessile lesion of the anterior bladder neck and multiple smaller papillary lesions throughout the bladder.
  • Following a transurethral resection of the bladder tumor with a diagnosis of muscle-invasive transitional cell carcinoma grade 3, a radical cystoprostatectomy was performed.
  • The diagnosis of transitional cell carcinoma was confirmed, but in addition, a different lesion was also incidentally found in the dome of the bladder.
  • This incidental lesion showed a prostatic adenocarcinoma arising from ectopic prostatic tissue within the bladder submucosa.
  • The prostate also showed prostatic adenocarcinoma, but this was minimal, low grade, and confined to the prostate gland, and thus it was felt to be unlikely to have metastasized to the bladder dome.
  • Adenocarcinoma arising in ectopic prostatic tissue is a rare finding and to our knowledge only 1 case has been previously described, occurring in the soft tissue adjacent to the prostate.
  • We report the first case of adenocarcinoma arising in ectopic prostatic tissue within the bladder.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Transitional Cell / pathology. Choristoma / pathology. Neoplasms, Multiple Primary / pathology. Prostate / pathology. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20807045.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


14. Hong JY, Choi MK, Uhm JE, Park MJ, Lee J, Park SH, Park JO, Kim WS, Kang WK, Lee HM, Choi HY, Lim H: Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract. Med Oncol; 2009;26(2):186-92
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract.
  • Non-transitional cell carcinomas of the urothelial tract comprise 5-10% of urothelial cancers.
  • Clinical information regarding the clinical behavior and chemotherapy outcome of non-transitional cell carcinomas of the urothelial tract are incomplete due to their rarity.
  • The object of this study was to evaluate the clinical features and the efficacy of palliative chemotherapy in advanced non-transitional cell carcinomas of the urothelial tract.
  • We analyzed the clinical records of 21 consecutive patients who received palliative chemotherapy for unresectable or metastatic non-transitional cell carcinomas of the urothelial tract between January 1995 and November 2007.
  • All the 21 patients received first-line chemotherapy with platinum-based regimens which are known to be effective in transitional cell urothelial carcinomas.
  • The primary sites of involvement were the bladder, urethra, urachus, and ureter in 43%, 29%, 19%, and 10% of the patients, respectively.
  • Adenocarcinoma was the most common histological type (67%); squamous cell carcinoma and small cell carcinoma comprised 24 and 10% of the histologic types, respectively.
  • Univariate analysis showed a better median overall survival in patients with adenocarcinoma, compared to non-adenocarcinomas (47 vs. 10 months, P = 0.049).
  • The median overall survival of patients who received platinum-based palliative chemotherapy for advanced non-transitional cell carcinomas was comparable to previous studies for patients with transitional cell carcinomas.
  • Adenocarcinomas appear to have a favorable prognosis for the survival of the patients who received platinum-based chemotherapy for advanced non-transitional cell carcinomas.
  • [MeSH-major] Carcinoma / drug therapy. Palliative Care. Urologic Neoplasms / drug therapy. Urothelium
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Female. Humans. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18988001.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


15. Gilligan T, Dreicer R: The atypical urothelial cancer patient: management of bladder cancers of non-transitional cell histology and cancers of the ureters and renal pelvis. Semin Oncol; 2007 Apr;34(2):145-53
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The atypical urothelial cancer patient: management of bladder cancers of non-transitional cell histology and cancers of the ureters and renal pelvis.
  • Non-transitional cell neoplasms of the bladder and upper tract transitional cell carcinomas (ureter and renal pelvis) represent only a small fraction of urothelial carcinomas.
  • [MeSH-major] Kidney Neoplasms / therapy. Ureteral Neoplasms / therapy. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / therapy. Carcinoma, Small Cell / therapy. Carcinoma, Squamous Cell / therapy. Humans. Kidney Pelvis. Schistosomiasis haematobia / complications. Urachus

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17382798.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 94
  •  go-up   go-down


16. Busto Martín LA, Janeiro Pais M, González Dacal J, Chantada Abal V, Busto Castañón L: Signet-ring cell adenocarcinoma of the bladder: case series between 1990-2009. Arch Esp Urol; 2010 Mar;63(2):150-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signet-ring cell adenocarcinoma of the bladder: case series between 1990-2009.
  • OBJECTIVES: To present a revision on the signet-ring cell bladder adenocarcinomas found in our department.
  • METHODS/RESULTS: We reviewed all the transurethral resections of the bladder (TURB) performed between 1990 and 2009 finding 9 cases of primary signet ring cell adenocarcinomas (4 pure and 5 mixed).
  • CONCLUSIONS: Signet-ring cell primary adenocarcinoma of the bladder is an uncommon type of tumor, with worse prognosis than transitional cell cancer.
  • [MeSH-major] Carcinoma, Signet Ring Cell. Urinary Bladder Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20378938.001).
  • [ISSN] 1576-8260
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


17. Lughezzani G, Sun M, Jeldres C, Alasker A, Budäus L, Shariat SF, Latour M, Widmer H, Duclos A, Jolivet-Tremblay M, Montorsi F, Perrotte P, Karakiewicz PI: Adenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortality. Urology; 2010 Feb;75(2):376-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortality.
  • OBJECTIVES: To compare stage at radical cystectomy (RC) and cancer-specific mortality (CSM) after RC between non-urachal adenocarcinoma (ADK) and urothelial carcinoma (UC) of the urinary bladder.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Carcinoma, Transitional Cell / mortality. Carcinoma, Transitional Cell / pathology. Cystectomy. Urinary Bladder Neoplasms / mortality. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010. Published by Elsevier Inc.
  • (PMID = 20022091.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Wright JL, Black PC, Brown GA, Porter MP, Kamat AM, Dinney CP, Lin DW: Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol; 2007 Dec;178(6):2302-6; discussion 2307
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder.
  • PURPOSE: Sarcomatoid carcinoma and carcinosarcoma of the bladder are rare tumors that contain epithelial and mesenchymal elements, and may portend a worse prognosis than conventional urothelial carcinoma.
  • We investigated the survival of patients with the 2 tumor subtypes compared to survival in those with urothelial carcinoma.
  • MATERIALS AND METHODS: Cases of sarcomatoid carcinoma, carcinosarcoma and high grade urothelial carcinoma of the bladder were identified from the Surveillance, Epidemiology and End Results Program.
  • RESULTS: Overall unadjusted survival rates for 46,515 patients with urothelial carcinoma, 135 with sarcomatoid carcinoma and 166 with carcinosarcoma were 77%, 54% and 48% at 1 year, and 47%, 37% and 17% at 5 years, respectively.
  • Sarcomatoid carcinoma and carcinosarcoma presented at a similar age but at a higher T stage and with more frequent regional and distant metastases compared to urothelial carcinoma.
  • On multivariate analysis patients with sarcomatoid carcinoma (HR 1.18, 95% CI 0.91-1.52) and carcinosarcoma (HR 2.00, 95% CI 1.65-2.41) were at higher risk for death compared to those with urothelial carcinoma.
  • Overall mortality was worse with carcinosarcoma than with sarcomatoid carcinoma (HR 1.70, 95% CI 1.23-2.34).
  • CONCLUSIONS: Compared to patients with urothelial carcinoma those with sarcomatoid carcinoma and carcinosarcoma present at a more advanced stage and are at greater risk for death even after adjusting for stage at presentation.
  • The survival rate of sarcomatoid carcinoma is better than that of carcinosarcoma, offering some justification for the continued differentiation of these tumor types for clinical prognostication.
  • [MeSH-major] Adenocarcinoma / mortality. Carcinoma, Transitional Cell / mortality. Carcinosarcoma / mortality. Urinary Bladder Neoplasms / mortality. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17936803.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA91846
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Raspollini MR, Comin CE, Crisci A, Chilosi M: The use of placental S100 (S100P), GATA3 and napsin A in the differential diagnosis of primary adenocarcinoma of the bladder and bladder metastasis from adenocarcinoma of the lung. Pathologica; 2010 Feb;102(1):33-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of placental S100 (S100P), GATA3 and napsin A in the differential diagnosis of primary adenocarcinoma of the bladder and bladder metastasis from adenocarcinoma of the lung.
  • Primary bladder adenocarcinoma accounts for 0.5-2% of all malignant bladder tumours.
  • Literature data indicate the bladder as the second most common site of metastatic genitourinary tumours, with the kidney as the most frequent location.
  • Secondary tumours of the bladder account for about 2.3% of all bladder malignancies encountered in surgical specimens.
  • Herein, we describe an adenocarcinoma deeply infiltrating the bladder wall, with no morphologic features of transitional cell carcinoma, in a patient with a previous diagnosis of primary lung adenocarcinoma, mixed subtype.
  • In this case, the use of a limited immunohistochemical panel including napsin A, a recently described highly sensitive marker for lung adenocarcinoma, GATA3 and S100P, two novel markers of urothelial differentiation, was of crucial importance in differentiating between lung adenocarcinoma metastatic to the bladder and primary bladder adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Aspartic Acid Endopeptidases / metabolism. Biomarkers, Tumor / metabolism. GATA3 Transcription Factor / metabolism. Lung Neoplasms. S100 Proteins / metabolism. Urinary Bladder Neoplasms

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731252.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GATA3 Transcription Factor; 0 / GATA3 protein, human; 0 / S100 Proteins; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / NAPSA protein, human
  •  go-up   go-down


20. Panebianco V, Sciarra A, Di Martino M, Bernardo S, Vergari V, Gentilucci A, Catalano C, Passariello R: Bladder carcinoma: MDCT cystography and virtual cystoscopy. Abdom Imaging; 2010 Jun;35(3):257-64
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder carcinoma: MDCT cystography and virtual cystoscopy.
  • Bladder carcinoma is the most common tumor among the low urinary tract, accounting for 90% of cancer cases.
  • Conventional cystoscopy represents the gold standard for diagnosis and local management of bladder carcinoma.
  • As the prevalence of transitional cell carcinoma is four-fold greater in men than in women, the endoscopic procedure presents objective difficulties related to the length and bending of male urethra.
  • We presents the CT cystography findings with virtual endoscopy correlation and bladder carcinoma appearance.
  • [MeSH-major] Cystoscopy / methods. Tomography, X-Ray Computed / methods. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Neoplasm Invasiveness. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19471998.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Lerner SP, Shen S: Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer. Urol Oncol; 2008 Sep-Oct;26(5):481-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer.
  • The prostate is commonly involved by transitional cell carcinoma (TCC) in patients with bladder cancer.
  • A number of clinicopathologic factors including multifocal carcinoma in situ, tumor location, and tumor stage are associated with prostatic TCC (pTCC).
  • Distinct patterns and extent of pTCC have been described and are associated with pathologic stage of the primary bladder tumor as well as prognosis.
  • Given the high incidence of pTCC and prostatic adenocarcinoma, radical cystoprostatectomy is the treatment of choice for loco-regional control for patients with T4a disease.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Neoplasms, Multiple Primary / pathology. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / pathology


22. Miura K, Kobayashi T, Funayama Y, Fukushima K, Ogawa H, Oyama A, Itoh A, Moriya T, Yamada T, Okumoto T, Shibata C, Sasaki I: Giant T4 rectal carcinoma mimicking urinary bladder adenocarcinoma accurately diagnosed by immunohistochemistry and successfully treated with total pelvic exenteration: report of a case. Surg Today; 2008;38(3):261-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant T4 rectal carcinoma mimicking urinary bladder adenocarcinoma accurately diagnosed by immunohistochemistry and successfully treated with total pelvic exenteration: report of a case.
  • A 54-year-old man, with the chief complaints of hematuria, pollakisuria, and pneumaturia, was referred to our hospital, with a diagnosis of giant urinary bladder adenocarcinoma with massive invasion to the rectum.
  • On the basis of the radiological diagnosis and findings of hematoxylin and eosin (H&E) of biopsy specimens, it was difficult to conclude whether the adenocarcinoma originated in the bladder or in the rectum.
  • The immunohistochemical staining of the biopsy specimens showed cytokeratin 7 (CK7)(-) and CK20(+), which supported the notion that the adenocarcinoma possibly originated from the rectum.
  • Although the prognosis of T4 bladder adenocarcinomas has been reported to be quite poor in comparison with that of transitional cell carcinomas, the postoperative prognosis of T4 rectal adenocarcinomas has been reported to be more favorable and such tumors are recommended to be surgically resected.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Pelvic Exenteration. Rectal Neoplasms / diagnosis. Rectal Neoplasms / surgery. Urinary Bladder Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18307003.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


23. Berberian JP, Goeman L, Allory Y, Abbou CC, Salomon L: Adenocarcinoma of ileal neobladder 20 years after cystectomy. Urology; 2006 Dec;68(6):1343.e9-10
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of ileal neobladder 20 years after cystectomy.
  • We present the case of a 67-year-old man with adenocarcinoma of the ileal neobladder 20 years after radical cystoprostatectomy for Stage pT2 transitional bladder cell cancer.
  • This observation supports the hypothesis that in an ileal neobladder morphologic and molecular changes can be observed similar to those in the development of colorectal carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Cystectomy / methods. Ileal Neoplasms / pathology. Urinary Diversion
  • [MeSH-minor] Aged. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Cystoscopy. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Reoperation. Time Factors. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17141834.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Gao ZL, Wu JT, Liu YJ, Shi L, Men CP, Zhang P, Liu QZ, Wang L: [Laparoscopic radical cystectomy for 43 patients with invasive bladder carcinoma]. Zhonghua Wai Ke Za Zhi; 2008 Apr 15;46(8):595-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic radical cystectomy for 43 patients with invasive bladder carcinoma].
  • OBJECTIVE: To report initial experience with laparoscopic radical cystectomy in 43 patients with invasive bladder carcinoma.
  • METHODS: From December 2003 to October 2006, 29 men and 14 women underwent laparoscopic radical cystectomy with extracorporeal-assisted urinary diversion for transitional cell carcinoma of the bladder (n=40), adenocarcinoma (n=2) and squamous cell arcinoma (n=1).
  • [MeSH-major] Cystectomy / methods. Laparoscopy. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18844055.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


25. Luo JH, Xie D, Chen W, Dai YP, Li XF, Tao Y, Zheng KL: [Correlation of clusterin expression to prognosis of bladder carcinoma]. Ai Zheng; 2005 Jun;24(6):743-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of clusterin expression to prognosis of bladder carcinoma].
  • BACKGROUND & OBJECTIVE: Clinically, molecular prognostic markers for bladder carcinoma are still rare.
  • Recently, up-regulation of clusterin protein has been suggested to relate with development and prognosis of several human cancers, but its relation with bladder cancer is unclear.
  • This study was to analyze correlation of expression of clusterin protein to clinicopathologic parameters and prognosis of bladder cancer with tissue chip.
  • METHODS: A tissue microarray containing 81 cases of bladder carcinoma was constructed.
  • RESULTS: Of the 81 cases of bladder cancer, 69 were detectable by immunohistochemistry, 32 (46.4%) of which showed overexpression of clusterin protein.
  • Expression of clusterin was negatively correlated with prognosis of bladder cancer patients (log-rank=5.88, P=0.015); the recurrence-free survival time of patients with overexpression of clusterin was shorter than that of patients with normal expression of clusterin (37.3 months vs. 48.8 months).
  • CONCLUSION: The overexpression of clusterin might be a molecular prognostic marker of bladder cancer.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Transitional Cell / metabolism. Clusterin / metabolism. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Prognosis. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946493.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Clusterin
  •  go-up   go-down


26. Rouache L, Cherif M, Tanneau Y, Gobet F, Pfister C: [Secondary appearance of a carcinoma in an excluded native bladder: Report of three cases]. Prog Urol; 2006 Nov;16(5):603-6
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Secondary appearance of a carcinoma in an excluded native bladder: Report of three cases].
  • [Transliterated title] Apparition secondaire d'un carcinome sur vessie native exclue: à propos de trois cas.
  • Cystectomy is usually performed, but sometimes the bladder is left in place due to the presence of a pelvic cloaca and the morbidity related to this type of surgery.
  • MATERIAL: The authors report three cases of patients treated by urinary diversion for a congenital malformation without primary resection of the bladder RESULTS: In the absence of any infectious complications, bladder carcinoma on an excluded native bladder was diagnosed at the age of 3 years, 4 years and 38 years, respectively.
  • Histological examination showed transitional cell carcinoma in two cases and gastrointestinal-type adenocarcinoma of the bladder in 1 case.
  • CONCLUSION: The risk of secondary development of carcinoma in an excluded bladder during management of (congenital urological malformations is not negligible.
  • The authors also recommend cystoscopy and urine cytology with lavage to detect degeneration of the bladder mucosa.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Transitional Cell / diagnosis. Urinary Bladder / abnormalities. Urinary Bladder Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175961.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


27. Mazzucchelli R, Barbisan F, Santinelli A, Scarpelli M, Galosi AB, Lopez-Beltran A, Cheng L, Kirkali Z, Montironi R: Prediction of prostatic involvement by urothelial carcinoma in radical cystoprostatectomy for bladder cancer. Urology; 2009 Aug;74(2):385-90
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of prostatic involvement by urothelial carcinoma in radical cystoprostatectomy for bladder cancer.
  • OBJECTIVES: To ascertain which variables of bladder urothelial carcinoma (UC) might be useful in predicting either UC involving the prostate (UCP) or incidental prostate adenocarcinoma in radical cystoprostatectomy specimens.
  • METHODS: The bladder and whole-mount prostate sections of 248 radical cystoprostatectomy specimens were reviewed.
  • Stepwise discriminant analysis was used to predict UCP or incidental prostate adenocarcinoma.
  • UC originated from the prostatic urethra and periurethral ducts in 78 (31.45%), and isolated direct extension of UC from the bladder was present in 16 patients (6.45%).
  • The periurethral ducts coexisted with direct extension of bladder UC in 11 patients (4.4%).
  • Prostate adenocarcinoma was identified in 123 patients (49.6%).
  • Carcinoma in situ and high-grade urothelial papillary carcinoma were seen in 8 (3.2%) and 5 (2.0%) patients, respectively.
  • The tumor was in the trigone and bladder neck in 160 patients (64.5%).
  • Stepwise discriminant analysis selected 3 variables of bladder UC (previous recurrence and location and number of foci) and correctly predicted the group in 72.2% of patients without and with UCP.
  • Discriminant analysis selected 2 variables of bladder UC (focality and previous recurrence) and correctly predicted the group in 57.7% of patients without and with prostate adenocarcinoma.
  • CONCLUSIONS: Our approach can identify bladder UC variables that could guide urologists in the selection of the most appropriate surgical procedure.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy. Prostatectomy. Prostatic Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasms, Multiple Primary / diagnosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19501882.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Castellan M, Gosalbez R, Perez-Brayfield M, Healey P, McDonald R, Labbie A, Lendvay T: Tumor in bladder reservoir after gastrocystoplasty. J Urol; 2007 Oct;178(4 Pt 2):1771-4; discussion 1774
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor in bladder reservoir after gastrocystoplasty.
  • PURPOSE: To our knowledge the risk of malignancy in patients with previous bladder augmentation with stomach is unknown.
  • We report 3 cases of gastric adenocarcinoma and 1 of transitional cell carcinoma after augmentation cystoplasty with stomach with long-term followup.
  • RESULTS: Four male patients had carcinoma after augmentation gastrocystoplasty.
  • Preoperative diagnosis was neurogenic bladder in 3 patients and posterior urethral valve in 1.
  • Three patients had gastric adenocarcinoma, while the other had poorly differentiated transitional cell carcinoma.
  • CONCLUSIONS: Patients who undergo bladder augmentation with a gastric remnant are at increased risk for malignancy, probably similar to that in patients with enterocystoplasty.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma, Transitional Cell / etiology. Gastric Mucosa / transplantation. Urinary Bladder Neoplasms / etiology. Urinary Diversion / adverse effects. Urinary Reservoirs, Continent / adverse effects
  • [MeSH-minor] Adolescent. Adult. Child. Humans. Male. Retrospective Studies. Risk Factors. Urinary Bladder / surgery. Urodynamics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707009.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Vauhkonen H, Böhling T, Eissa S, Shoman S, Knuutila S: Can bladder adenocarcinomas be distinguished from schistosomiasis-associated bladder cancers by using array comparative genomic hybridization analysis? Cancer Genet Cytogenet; 2007 Sep;177(2):153-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can bladder adenocarcinomas be distinguished from schistosomiasis-associated bladder cancers by using array comparative genomic hybridization analysis?
  • Bladder cancer is the most common malignancy in many tropical and subtropical areas, correlating well with the endemicity of schistostomiasis.
  • The majority of schistostomiasis-associated (SA) bladder cancers are squamous cell cancers, whereas the majority of non-SA cases in the Western world are transitional cell cancers, suggesting different carcinogenetic mechanisms.
  • Comparison of the DNA copy number profiles to previously reported profiles of SA transitional cell carcinoma and squamous cell carcinoma revealed similarities (e.g., gains at 5p and 8q), as well as differences (e.g., TCC- and SCC-associated losses at 18p and 20p, and adenocarcinoma-associated gains at 20q).
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Carcinoma, Transitional Cell / genetics. Gene Expression Profiling. Nucleic Acid Hybridization. Schistosomiasis / complications. Urinary Bladder Neoplasms / genetics

  • Genetic Alliance. consumer health - Schistosomiasis.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Genet Cytogenet. 2008 Jan 15;180(2):160-2 [18206545.001]
  • (PMID = 17854674.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


30. Tavora F, Epstein JI: Urothelial carcinoma with abundant myxoid stroma. Hum Pathol; 2009 Oct;40(10):1391-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urothelial carcinoma with abundant myxoid stroma.
  • Thirteen cases of urothelial carcinoma with myxoid features were collected over 9 years.
  • Cases with any distinct adenocarcinoma component were excluded from the study.
  • All cases involved the bladder with one of the cases involving a bladder diverticulum.
  • Treatment included transurethral resection of the bladder only in 6 patients, transurethral resection of the bladder with subsequent intravesical bacillus Calmette-Guérin treatment in 4 patients, radical cystectomy only in 2 patients, and neoadjuvant chemotherapy followed by cystectomy in 1 patient.
  • In all cases, the myxoid stroma was associated with invasive urothelial carcinoma.
  • The percentage of invasive urothelial carcinoma that had myxoid stroma ranged from 5% to 95% (mean, 50%).
  • An unusual finding was the presence of invasive low-grade urothelial carcinoma associated with myxoid stroma in 5 cases, 4 of which had an overlying low-grade papillary urothelial carcinoma component.
  • Urothelial carcinoma associated with the extracellular myxoid matrix was positive for MUC5 in 3 cases and for MUC2 in 2 cases.
  • The current study describes a rare variant of urothelial carcinoma that may be confused with primary or secondary adenocarcinoma of the bladder, which can have therapeutic and prognostic implications.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19535127.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


31. Falkensammer C, Gozzi C, Hager M, Maier H, Bartsch G, Höltl L, Rehder P: Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma. Urology; 2005 Jan;65(1):175
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette-Guérin therapy for superficial bladder carcinoma.
  • We report a case of bilateral tuberculous-like epididymo-orchitis occurring 3 years after intravesical bacille Calmette-Guérin instillation therapy in an 83-year-old patient with proven superficial bladder carcinoma.
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Administration, Intravesical. Aged. Aged, 80 and over. Carcinoma in Situ / therapy. Carcinoma, Transitional Cell / therapy. Combined Modality Therapy. Humans. Instillation, Drug. Male. Neoplasms, Multiple Primary. Orchiectomy. Prostatic Neoplasms / radiotherapy. Prostatic Neoplasms / surgery. Time Factors. Transurethral Resection of Prostate. Tuberculoma / etiology. Tuberculoma / surgery. Urinary Bladder Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667898.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down


32. Ghoneim MA, Abdel-Latif M, el-Mekresh M, Abol-Enein H, Mosbah A, Ashamallah A, el-Baz MA: Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol; 2008 Jul;180(1):121-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later.
  • PURPOSE: We performed a critical analysis of the results of radical cystectomy for invasive bladder carcinoma treated at 1 center.
  • MATERIALS AND METHODS: Between 1970 and 2000, 2,090 men and 630 women with invasive bladder cancer were treated with 1-stage radical cystectomy and urinary diversion.
  • Squamous tumors accounted for 49.4% of cases, transitional cell carcinoma for 36.4% and adenocarcinoma for 9.6%.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2008 Jul;180(1):12-3 [18485379.001]
  • (PMID = 18485392.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Higgins JP, Kaygusuz G, Wang L, Montgomery K, Mason V, Zhu SX, Marinelli RJ, Presti JC Jr, van de Rijn M, Brooks JD: Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray. Am J Surg Pathol; 2007 May;31(5):673-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
  • The morphologic distinction between prostate and urothelial carcinoma can be difficult.
  • To identify novel diagnostic markers that may aid in the differential diagnosis of prostate versus urothelial carcinoma, we analyzed expression patterns in prostate and bladder cancer tissues using complementary DNA microarrays.
  • Using tissue microarrays, a polyclonal antiserum against S100P protein stained 86% of 295 urothelial carcinomas while only 3% of 260 prostatic adenocarcinomas and 1% of 133 renal cell carcinomas stained.
  • A commercially available monoclonal antibody against S100P stained 78% of 300 urothelial carcinomas while only 2% of 256 prostatic adenocarcinomas and none of 137 renal cell carcinomas stained.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Calcium-Binding Proteins / metabolism. Carcinoma, Transitional Cell / metabolism. GATA3 Transcription Factor / metabolism. Neoplasm Proteins / metabolism. Urologic Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Kidney Neoplasms / genetics. Kidney Neoplasms / metabolism. Kidney Neoplasms / pathology. Male. Nephrectomy. Oligonucleotide Array Sequence Analysis. Prostatic Neoplasms / genetics. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology. Tissue Array Analysis. Urinary Bladder Neoplasms / genetics. Urinary Bladder Neoplasms / metabolism. Urinary Bladder Neoplasms / pathology. Urothelium / metabolism. Urothelium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460449.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / DNA, Neoplasm; 0 / GATA3 Transcription Factor; 0 / GATA3 protein, human; 0 / Neoplasm Proteins; 0 / S100P protein, human
  •  go-up   go-down


34. Martínez-Rodríguez M, Ramos D, Soriano P, Subramaniam M, Navarro S, Llombart-Bosch A: Poorly differentiated adenocarcinomas of prostate versus high-grade urothelial carcinoma of the bladder: a diagnostic dilemma with immunohistochemical evaluation of 2 cases. Int J Surg Pathol; 2007 Apr;15(2):213-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated adenocarcinomas of prostate versus high-grade urothelial carcinoma of the bladder: a diagnostic dilemma with immunohistochemical evaluation of 2 cases.
  • The differential diagnosis between carcinoma of the urinary bladder and adenocarcinoma of the prostate can be difficult, especially in the poorly differentiated forms infiltrating the neighboring organs.
  • The first is an infiltration of the bladder by a poorly differentiated adenocarcinoma of the prostate, which was clinically suspected as a papillary urothelial neoplasm.
  • The second is a collision tumor composed of prostatic adenocarcinoma and urothelial carcinoma observed on a core needle biopsy of the prostate.
  • In both cases, a large panel of immunohistochemical markers were used and demonstrated positivity for prostate-specific antigen and alpha methyl racemase in the prostatic carcinomas and immunoreactivity for CK7, CK20, Ag 34betaE12, and p53 in the urothelial carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Transitional Cell / pathology. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17478786.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


35. Fan J, Ma LJ, Xia SJ, Yu L, Fu Q, Wu CQ, Huang XH, Jiang JM, Tang XD: Association between clinical characteristics and expression abundance of RTKN gene in human bladder carcinoma tissues from Chinese patients. J Cancer Res Clin Oncol; 2005 Mar;131(3):157-62
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between clinical characteristics and expression abundance of RTKN gene in human bladder carcinoma tissues from Chinese patients.
  • PURPOSE: Bladder carcinoma is the most common urological malignancy in China.
  • We therefore investigated the mRNA expression of RTKN gene in clinic malignant bladder carcinoma and explored the relationship between the novel gene and the cancer.
  • METHODS: Total RNA was extracted from 33 surgically resected specimens of bladder carcinoma and 19 specimens of tumor-free bladder tissues.
  • After the optimal reverse-transcription polymerase chain reaction condition was established, the mRNA expression levels of the RTKN gene in the lesions and tumor-free bladder tissues were examined semiquantitatively, and the relationships between expression levels of RTKN and clinical pathological features were analyzed.
  • RESULTS: The expression of RTKN gene mRNA in 33 human bladder carcinoma tissues was significantly higher than that in 19 human tumor-free bladder tissues (0.937+/-0.103 vs. 0.350+/-0.082).
  • The average ratio of RTKN expression in neoplasms to that in tumor-free bladder tissues was 0.350+/-0.164.
  • Although the chi(2) test demonstrated a statistically nonsignificant differences in RTKN expression between tumor stages Ta, T(1), and T(2) overall in the 33 human bladder carcinoma, the t test showed that there were statistically significant differences between solitary and multiple tumors, between the paired group aged younger or older than 70 years in 27 de novo bladder carcinoma patients, and between the groups with tumor larger or smaller than 2.25 cm(3).
  • CONCLUSIONS: These results suggest that the RTKN gene is involved in bladder carcinogenesis and progression in bladder carcinoma, indicating that RTKN gene could be a molecular target in cancer therapy.
  • [MeSH-major] Asian Continental Ancestry Group / genetics. Carcinoma, Transitional Cell / genetics. Carcinoma, Transitional Cell / pathology. Intracellular Signaling Peptides and Proteins / genetics. Urinary Bladder Neoplasms / genetics. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Down-Regulation. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15599595.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / RTKN protein, human
  •  go-up   go-down


36. Kaufman DS, Shipley WU, Feldman AS: Bladder cancer. Lancet; 2009 Jul 18;374(9685):239-49
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder cancer.
  • Bladder cancer is a heterogeneous disease, with 70% of patients presenting with superficial tumours, which tend to recur but are generally not life threatening, and 30% presenting as muscle-invasive disease associated with a high risk of death from distant metastases.
  • The main presenting symptom of all bladder cancers is painless haematuria, and the diagnosis is established by urinary cytology and transurethral tumour resection.
  • Intravesical treatment is used for carcinoma in situ and other high grade non-muscle-invasive tumours.
  • Bladder preservation with transurethral tumour resection, radiation, and chemotherapy can in some cases be equally curative.
  • We discuss bladder preserving approaches, combination chemotherapy including new agents, targeted therapies, and advances in molecular biology.
  • [MeSH-major] Urinary Bladder Neoplasms
  • [MeSH-minor] Adenocarcinoma / epidemiology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Transitional Cell / epidemiology. Chemotherapy, Adjuvant. Combined Modality Therapy. Cystectomy. Cystoscopy. Diagnosis, Differential. Hematuria / etiology. Humans. Molecular Biology. Neoadjuvant Therapy. Neoplasm Staging. Prostatectomy. Risk Factors. Sensitivity and Specificity. Survival Rate. United States / epidemiology. Urinary Diversion


37. Kalisvaart JF, Katsumi HK, Ronningen LD, Hovey RM: Bladder cancer in spinal cord injury patients. Spinal Cord; 2010 Mar;48(3):257-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder cancer in spinal cord injury patients.
  • OBJECTIVE: Spinal cord injury is a known risk factor for bladder cancer.
  • The risk of bladder cancer has been reported at 16-28 times higher than the general population.
  • We examined the characteristics of bladder cancers in a spinal cord injury (SCI) population.
  • METHODS: We reviewed SCI patients seen and diagnosed with bladder tumors between January 1983 and January 2007.
  • Data collected included time since diagnosis, method of diagnosis, form of bladder management, pathologic type, treatment of the tumor, and outcome.
  • RESULTS: A total of 32 patients with bladder cancer were identified out of 1319 seen.
  • Tumors found were 46.9% squamous cell carcinoma (SCC), 31.3% transitional cell carcinoma (TCC), 9.4% adenocarcinoma, and 12.5% mixed TCC and SCC.
  • The primary form of bladder management was 44% urethral catheter for a mean of 33.3 years, 48% external catheter for a mean of 37.4 years, and 8% intermittent catheterization for a mean of 24.5 years.
  • Over 50% of patients diagnosed with bladder cancer in our population did not have an indwelling catheter.
  • This suggests that the neurogenic bladder, not the indwelling catheter, may be the risk factor for bladder cancer.
  • Urologists should consider diligent, long-term screening of all patients with SCI for bladder cancer and not just those with indwelling catheters.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma, Squamous Cell / etiology. Carcinoma, Transitional Cell / etiology. Spinal Cord Injuries / complications. Urinary Bladder Neoplasms / etiology


38. Demirci H, Nelson CC, Shields CL, Eagle RC Jr, Shields JA: Eyelid sebaceous carcinoma associated with Muir-Torre syndrome in two cases. Ophthal Plast Reconstr Surg; 2007 Jan-Feb;23(1):77-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid sebaceous carcinoma associated with Muir-Torre syndrome in two cases.
  • We report the rare but serious association between sebaceous carcinoma of eyelid and Muir-Torre syndrome in two cases, a 79-year-old woman and 54-year-old man.
  • A history of multiple primary colon cancers was present in both patients, associated transitional cell carcinoma of bladder and renal cancer in one patient and prostate cancer in the other.
  • Histopathology revealed sebaceous carcinoma of eyelid and conjunctiva.
  • Muir-Torre syndrome was diagnosed on the basis of sebaceous carcinoma, associated with multiple visceral malignancies in both patients.
  • We conclude that patients with sebaceous carcinoma should have evaluation for visceral malignancies, mainly colon cancer.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Eyelid Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Neoplastic Syndromes, Hereditary / pathology. Sebaceous Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma, Transitional Cell. Colonic Neoplasms / pathology. Cryotherapy. Female. Humans. Kidney Neoplasms / pathology. Male. Middle Aged. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237705.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


39. Andreeva IuIu, Zavalishina LE, Frank GA: [Classification of urinary bladder tumors]. Arkh Patol; 2006 Sep-Oct;68(5):46-53
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Classification of urinary bladder tumors].
  • The paper outlines the topical aspects of the current classification of urinary bladder epithelial tumors.
  • Difficulties in the microscopic diagnosis of different types of urothelial carcinoma, the specific features of gradation and staging, and possibilities of differential diagnosis are presented.
  • [MeSH-major] Urinary Bladder Neoplasms / classification
  • [MeSH-minor] Adenocarcinoma, Clear Cell / classification. Adenocarcinoma, Clear Cell / pathology. Adenoma, Villous / classification. Adenoma, Villous / pathology. Carcinoma, Papillary / classification. Carcinoma, Papillary / pathology. Carcinoma, Small Cell / classification. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / classification. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / classification. Carcinoma, Transitional Cell / pathology. Humans. Urothelium / pathology. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17144533.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Lectures
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


40. Colombo Jr JR, Desai M, Canes D, Frota R, Haber GP, Moinzadeh A, Tuerk I, Desai MR, Gill IS: Laparoscopic partial cystectomy for urachal and bladder cancer. Clinics (Sao Paulo); 2008 Dec;63(6):731-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic partial cystectomy for urachal and bladder cancer.
  • PURPOSE: To report our initial experiences with laparoscopic partial cystectomy for urachal and bladder malignancy.
  • MATERIALS AND METHODS: Between March 2002 and October 2004, laparoscopic partial cystectomy was performed in 6 cases at 3 institutions; 3 cases were urachal adenocarcinomas and the remaining 3 cases were bladder transitional cell carcinomas.
  • Gross hematuria was the presenting symptom in all patients, and diagnosis was established with trans-urethral resection bladder tumor in 2 patients and by means of cystoscopic biopsy in the remaining 4 patients.
  • One patient with para-ureteral diverticulum transitional cell carcinoma required concomitant ureteral reimplantation.
  • Frozen section evaluations of bladder margins were routinely obtained and were negative for cancer in all cases.
  • Final histopathology confirmed urachal adenocarcinoma in 3 cases and bladder transitional cell carcinoma in 3 cases.
  • CONCLUSIONS: Laparoscopic partial cystectomy in carefully selected patients with urachal and bladder cancer is feasible and safe, offering a promising and minimally invasive alternative for these patients.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Urachus / surgery. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Urachal cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2004 Sep;172(3):878-81 [15310988.001]
  • [Cites] Urol Clin North Am. 1992 Nov;19(4):701-11 [1441027.001]
  • [Cites] J Laparoendosc Surg. 1993 Apr;3(2):161-5 [8518471.001]
  • [Cites] Urology. 1993 Dec;42(6):635-9 [8256396.001]
  • [Cites] J Urol. 1994 Feb;151(2):365-6 [8283526.001]
  • [Cites] BJU Int. 2007 Jul;100(1):137-42 [17552961.001]
  • [Cites] Arch Esp Urol. 1999 Jul-Aug;52(6):577-85 [10484841.001]
  • [Cites] Int Braz J Urol. 2004 May-Jun;30(3):192-8 [15689245.001]
  • [Cites] Urology. 2006 Apr;67(4):837-43 [16618570.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):712-20 [16826585.001]
  • [Cites] Fertil Steril. 1996 Dec;66(6):920-4 [8941055.001]
  • (PMID = 19060992.001).
  • [ISSN] 1980-5322
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Other-IDs] NLM/ PMC2664270
  •  go-up   go-down


41. Crow P, Molckovsky A, Stone N, Uff J, Wilson B, WongKeeSong LM: Assessment of fiberoptic near-infrared raman spectroscopy for diagnosis of bladder and prostate cancer. Urology; 2005 Jun;65(6):1126-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of fiberoptic near-infrared raman spectroscopy for diagnosis of bladder and prostate cancer.
  • OBJECTIVES: To determine whether a fiberoptic Raman system, suitable for in vivo use, is able to differentiate between benign and malignant bladder and prostate pathologic findings in vitro.
  • Laboratory studies have shown that the technique can be used to identify and characterize transitional cell carcinoma and prostate adenocarcinoma in vitro.
  • METHODS: A total of 220 Raman spectra were recorded from 29 snap-frozen bladder samples collected at cystoscopic procedures, and 197 Raman spectra were recorded from 38 snap-frozen prostate samples collected at transurethral resection of the prostate.
  • The spectra were correlated with the histologic features and used to construct separate diagnostic algorithms for the bladder and prostate.
  • RESULTS: The bladder algorithm was able to differentiate benign samples (normal and cystitis) from malignant samples (transitional cell carcinoma), with an overall accuracy of 84%.
  • CONCLUSIONS: The results of this study have demonstrated that the clinical Raman system can provide an accurate and objective method to diagnose prostate and bladder cancer in vitro.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Transitional Cell / diagnosis. Prostatic Neoplasms / diagnosis. Spectroscopy, Near-Infrared. Urinary Bladder Neoplasms / diagnosis


42. Ersoy A, Filiz G, Ersoy C, Kahvecioglu S, Kanat O, Vuruskan H, Gullulu M: Synchronous carcinomas of stomach and bladder together with AA amyloidosis. Nephrology (Carlton); 2006 Apr;11(2):120-3
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous carcinomas of stomach and bladder together with AA amyloidosis.
  • Here, a case of diagnosed AA amyloidosis associated with synchronous carcinomas of stomach and bladder complicated with nephrotic syndrome and renal failure is reported.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Aged. Carcinoma, Transitional Cell / complications. Carcinoma, Transitional Cell / diagnosis. Fatal Outcome. Humans. Male. Stomach Neoplasms / complications. Stomach Neoplasms / diagnosis. Urinary Bladder Neoplasms / complications. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Amyloidosis AA.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16669973.001).
  • [ISSN] 1320-5358
  • [Journal-full-title] Nephrology (Carlton, Vic.)
  • [ISO-abbreviation] Nephrology (Carlton)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


43. Romics I, Riesz P, Keszthelyi A, Pánovics J: [Experiences with radical cystectomy combined with urinary diversion by ureteral sigmapouch (Mainz-pouch II) in bladder cancer patients]. Orv Hetil; 2006 Sep 3;147(35):1691-6
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experiences with radical cystectomy combined with urinary diversion by ureteral sigmapouch (Mainz-pouch II) in bladder cancer patients].
  • INTRODUCTION: The tumour of the bladder is the third most frequent urological malignancy.
  • After removing the bladder; a sufficient urinary diversion should be performed.
  • 94% of the cases were transitional cell cancers, 3 (4%) of them had adenocarcinoma and one leiomyosarcoma.
  • [MeSH-major] Cystectomy / methods. Ureter / surgery. Urinary Bladder Neoplasms / surgery. Urinary Diversion / methods
  • [MeSH-minor] Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Transitional Cell / surgery. Female. Humans. Leiomyosarcoma / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Nephrostomy, Percutaneous. Quality of Life. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17051745.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


44. Abd El Gawad IA, Moussa HS, Nasr MI, El Gemae EH, Masooud AM, Ibrahim IK, El Hifnawy NM: Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer. J Egypt Natl Canc Inst; 2005 Sep;17(3):193-202
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer.
  • PURPOSE: The diagnostic efficacy of Nuclear Matrix Protein-22 (NMP-22), bladder tumor antigen (BTA TRAK), and telomerase activity was evaluated in urine in a trial to assess their value in the detection of bladder cancer and to compare it to that of routine urine cytology.
  • SUBJECTS AND METHODS: The study included 46 newly diagnosed bladder cancer patients, diagnosed by cystoscopy and histopathological typing, in addition to 20 patients with benign bladder lesions and 20 healthy age and sex matched volunteers as a control group.
  • Most patients (27/46) had transitional cell carcinoma (TCC), 17/46 had squamous cell carcinoma (SCC), while only 2 patients had adenocarcinoma.
  • For bilharzial cancer bladder respective sensitivities were 69.6%, 95.6%, 100% and 73.9%, while for nonbilharzial cancer bladder the respective sensitivities were 39.1%, 87%, 100% and 87%.
  • CONCLUSION: BTA showed the highest sensitivity in all the studied parameters in the bladder cancer group, bilharzial bladder cancer subgroup, and non bilharzial bladder subgroup, (100%), while the highest specificity was recorded with urine cytology (100%), followed by telomerase (95%), then BTA (92.5%), and lastly NMP- 22 (87.5%).
  • [MeSH-major] Antigens, Neoplasm / urine. Biomarkers, Tumor / urine. Nuclear Proteins / urine. Telomerase / urine. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / urine
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / urine. Adult. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / urine. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / urine. Female. Humans. Male. Middle Aged. Schistosomiasis haematobia / complications

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799657.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / bladder tumor-associated antigen; 0 / nuclear matrix protein 22; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


45. Chalasani V, Macek P, O'Neill GF, Barret W: Ureteric stricture secondary to unusual extension of prostatic adenocarcinoma. Can J Urol; 2010 Feb;17(1):5031-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ureteric stricture secondary to unusual extension of prostatic adenocarcinoma.
  • This article describes an unusual finding in a patient who presented with an adenocarcinoma of the prostate and right hydronephrosis.
  • DRE was consistent with cT3 carcinoma.
  • Cystoscopy showed an exophytic superficial transitional cell carcinoma (TCC) of the bladder and a transrectal biopsy of the prostate confirmed adenocarcinoma Gleason score 4+3.
  • Staging investigations (CT pelvis and bone scan) were negative; androgen deprivation therapy was therefore initiated for the prostatic adenocarcinoma.
  • Final histology showed prostatic adenocarcinoma infiltrating the adventitia of the entire ureter up to the level of the renal pelvis.
  • A rare cause of ureteric stricture, contiguous spread of prostatic adenocarcinoma, should be considered in the differential diagnosis of patients presenting with upper tract obstruction and a known history of prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology. Ureter / pathology. Ureteral Obstruction / etiology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20156388.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


46. Moussa O, Yordy JS, Abol-Enein H, Sinha D, Bissada NK, Halushka PV, Ghoneim MA, Watson DK: Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer. Cancer Res; 2005 Dec 15;65(24):11581-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic and functional significance of thromboxane synthase gene overexpression in invasive bladder cancer.
  • TXAS was among the genes we identified based on its overexpression in invasive bladder tumors.
  • TXAS is overexpressed in common forms of bladder tumors: 69 of 97 (71.1%) transitional cell carcinoma (TCC), 38 of 53 (71.6%) squamous cell carcinoma, and 5 of 11 (45.5%) adenocarcinoma relative to nontumor tissue.
  • TXAS mRNA expression was found to be an independent prognostic marker for patients with bladder cancer.
  • Treatment of bladder cancer cell lines (T24 and TCC-SUP) with TXAS inhibitors and TXA(2) (TP) receptor antagonists reduced cell growth, migration, and invasion, whereas TP agonists stimulated cell migration and invasion.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Thromboxane-A Synthase / metabolism. Urinary Bladder Neoplasms / enzymology
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adult. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / enzymology. Carcinoma, Transitional Cell / genetics. Carcinoma, Transitional Cell / pathology. Cell Movement. Cell Proliferation. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Thromboxane / agonists. Receptors, Thromboxane / antagonists & inhibitors. Receptors, Thromboxane / metabolism. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357168.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA069222; United States / NCI NIH HHS / CA / R21 CA106570
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Thromboxane; EC 5.3.99.5 / Thromboxane-A Synthase
  •  go-up   go-down


47. Kong CH, Singam P, Hong GE, Cheok LB, Azrif M, Tamil AM, Zainuddin ZM: Clinicopathological features of bladder tumours in a single institution in Malaysia. Asian Pac J Cancer Prev; 2010;11(1):149-52
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of bladder tumours in a single institution in Malaysia.
  • OBJECTIVE: To determine the clinicopathological features of bladder tumours encountered over a five year period in Universiti Kebangsaan Malaysia Medical Centre.
  • METHODS: Medical records of bladder tumour cases from 2005 till 2009 were retrospectively reviewed and tabulated.
  • The main histopathology was transitional cell carcinoma (TCC) (90.4%), followed by adenocarcinoma (6%), squamous cell carcinoma (1.2%), leiomyoma (1.2%) and myeloid sarcoma (1.2%).
  • There were ten radical cystectomies performed for transitional cell carcinomas; two had neobladder reconstruction whereas the other eight had ileal conduits.
  • All the adenocarcinomas and squamous cell carcinomas were treated by radiotherapy due to the advanced stage of the disease while the myeloid sarcoma received chemotherapy.
  • CONCLUSION: The incidence of bladder tumours is highest among the Chinese.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / secondary. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593947.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


48. Dresen RC, Beets GH, Vliegen RF, Creytens DH, Beets-Tan RG: Linitis plastica of the rectum secondary to bladder carcinoma: a report of two cases and its MR features. Br J Radiol; 2008 Oct;81(970):e249-51
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Linitis plastica of the rectum secondary to bladder carcinoma: a report of two cases and its MR features.
  • Rectal linitis plastica (RLP) is a circumferentially infiltrating intramural anaplastic carcinoma that results in a rigid constricted rectum with thickened walls.
  • RLP secondary to bladder cancer is rarely described in the English literature.
  • We present the first report of the MR features of secondary rectal linitis plastica from a bladder carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Transitional Cell / secondary. Linitis Plastica / secondary. Rectal Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18796553.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


49. Azuma H, Kotake Y, Yamamoto K, Sakamoto T, Kiyama S, Ubai T, Inamoto T, Takahara K, Matsuki M, Segawa N, Shibahara N, Katsuoka Y: Effect of combined therapy using balloon-occluded arterial infusion of cisplatin and hemodialysis with concurrent radiation for locally invasive bladder cancer. Am J Clin Oncol; 2008 Feb;31(1):11-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of combined therapy using balloon-occluded arterial infusion of cisplatin and hemodialysis with concurrent radiation for locally invasive bladder cancer.
  • OBJECTIVE: We tested the usefulness of combined therapy using balloon-occluded arterial infusion (BOAI) of cisplatin and hemodialysis, which delivers an extremely high concentration of cisplatin to the site of a tumor without systemic adverse effects, with concurrent radiation in patients with locally advanced bladder cancer.
  • METHODS: Patients underwent transurethral resection of the bladder tumor followed by BOAI of cisplatin (100, 200, or 300 mg) concurrent with hemodialysis, via both common iliac veins, for 2 hours after initiation of BOAI.
  • All patients with histologically confirmed transitional cell carcinoma stage T2 or T3 (29 patients) achieved a complete response and were able to retain their bladder with no evidence of recurrent disease or distant metastasis at a mean follow-up of 132 weeks (range 8-648 weeks) after therapy.
  • Patients with stage T4 tumors, besides transitional cell carcinoma, or lymph node involvement had stable or progressive disease.
  • CONCLUSION: This therapy is a new strategy for patients with locally advanced bladder cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Balloon Occlusion. Cisplatin / administration & dosage. Infusions, Intra-Arterial. Renal Dialysis / methods. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / therapy. Choriocarcinoma / pathology. Choriocarcinoma / therapy. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376222.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


50. Prout GR Jr, Wesley MN, Yancik R, Ries LA, Havlik RJ, Edwards BK: Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer; 2005 Oct 15;104(8):1638-47
MedlinePlus Health Information. consumer health - Seniors' Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study.
  • BACKGROUND: Bladder carcinoma often occurs in older patients who also may have other comorbid conditions that could influence the administration of surgical therapy.
  • The current study was conducted to describe the distribution of comorbid conditions in patients with bladder carcinoma and ascertain whether these conditions, as grouped by the American Society of Anesthesiologists physical status classification, affected the choice of surgical therapy.
  • A random sample of newly diagnosed bladder carcinoma patients were stratified according to registry, age group (ages 55-64 yrs, ages 65-74 yrs, and age 75 yrs and older), and gender.
  • [MeSH-major] Aging / physiology. Comorbidity. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / surgery. Cystectomy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Prognosis. SEER Program. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • [CommentIn] Cancer. 2005 Oct 15;104(8):1563-6 [16116607.001]
  • [CommentIn] Cancer. 2005 Oct 15;104(8):1559-62 [16118803.001]
  • (PMID = 16130136.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Fröhlich C, Albrechtsen R, Dyrskjøt L, Rudkjaer L, Ørntoft TF, Wewer UM: Molecular profiling of ADAM12 in human bladder cancer. Clin Cancer Res; 2006 Dec 15;12(24):7359-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular profiling of ADAM12 in human bladder cancer.
  • The purpose of this study was to determine the gene and protein expression profiles of ADAM12 in different grades and stages of bladder cancer.
  • EXPERIMENTAL DESIGN: ADAM12 gene expression was evaluated in tumors from 96 patients with bladder cancer using a customized Affymetrix GeneChip.
  • Gene expression in bladder cancer was validated using reverse transcription-PCR, quantitative PCR, and in situ hybridization.
  • Protein expression was evaluated by immunohistochemical staining on tissue arrays of bladder cancers.
  • RESULTS: ADAM12 mRNA expression was significantly up-regulated in bladder cancer, as determined by microarray analysis, and the level of ADAM12 mRNA correlated with disease stage.
  • Finally, ADAM12 could be detected in the urine by Western blotting; ADAM12 was present in higher levels in the urine from patients with bladder cancer compared with urine from healthy individuals.
  • Significantly, following removal of tumor by surgery, in most bladder cancer cases examined, the level of ADAM12 in the urine decreased and, upon recurrence of tumor, increased.
  • CONCLUSIONS: ADAM12 is a promising biomarker of bladder cancer.
  • [MeSH-major] ADAM Proteins / metabolism. Carcinoma, Transitional Cell / metabolism. Gene Expression Profiling / methods. Membrane Proteins / metabolism. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenocarcinoma / urine. Adult. Aged. Aged, 80 and over. Amyloid Precursor Protein Secretases / metabolism. Animals. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Carcinoma, Squamous Cell / urine. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Mammary Neoplasms, Experimental / metabolism. Mammary Neoplasms, Experimental / pathology. Mice. Middle Aged. Mucous Membrane / metabolism. Neoplasm Recurrence, Local / urine. Neoplasm Staging

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17189408.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 3.4.- / Amyloid Precursor Protein Secretases; EC 3.4.24.- / ADAM 12 protein; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAM8 protein, human; EC 3.4.24.81 / ADAM10 protein, human
  •  go-up   go-down


52. Dickson BC, Fornasier VL, Streutker CJ, Stewart RJ: Ureteric obstruction: an unusual presentation of metastatic colon carcinoma. Can J Urol; 2007 Apr;14(2):3526-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ureteric obstruction: an unusual presentation of metastatic colon carcinoma.
  • We present the case of a 78-year-old male who presented to clinic for follow-up of a papillary transitional cell carcinoma of the urinary bladder.
  • Notably, the patient also had a history of colorectal resection for an adenocarcinoma.
  • Upon surgical resection the lesion was found to be an adenocarcinoma, morphologically consistent with a metastasis from the patient's primary colonic adenocarcinoma.
  • This case illustrates a diagnostically challenging situation, with metastatic colonic carcinoma to the ureter occurring in a patient with two previously documented malignancies.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Ureteral Neoplasms / secondary. Ureteral Obstruction / etiology
  • [MeSH-minor] Aged. Carcinoma, Transitional Cell / pathology. Humans. Male. Neoplasms, Second Primary. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17466162.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


53. Husmann DA, Rathbun SR: Long-term follow up of enteric bladder augmentations: the risk for malignancy. J Pediatr Urol; 2008 Oct;4(5):381-5; discussion 386
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow up of enteric bladder augmentations: the risk for malignancy.
  • OBJECTIVE: To determine the risk of bladder cancer following enteric bladder augmentation.
  • MATERIALS AND METHODS: Patients followed for care after an enteric bladder augmentation have been entered into a registry; individuals followed for a minimum of 10 years were evaluated.
  • RESULTS: The study criteria were met by 153 patients.
  • Indications for bladder augmentation were neurogenic bladder in 97, exstrophy in 38 and posterior urethral valves in 18.
  • Two patients with neurogenic bladder developed transitional cell carcinoma; both were heavy smokers (>50 pack per year history).
  • Two patients with a history of posterior urethral valves and renal transplantation developed adenocarcinoma of the enteric augment.
  • Three patients with bladder exstrophy developed multifocal adenocarcinoma of the augmented bladder.
  • CONCLUSIONS: Malignancy following enteric bladder augmentation arose in 4.5% (7/153) of our patients and was associated with coexisting carcinogenic stimuli (prolonged tobacco/chronic immunosuppressive exposure), or alternatively with the inherent risk of malignancy existing with bladder exstrophy.
  • [MeSH-major] Urinary Bladder Diseases / surgery. Urinary Bladder Neoplasms / epidemiology. Urinary Bladder Neoplasms / etiology
  • [MeSH-minor] Child. Follow-Up Studies. Humans. Intestines / transplantation. Risk Assessment. Risk Factors. Time Factors. Urinary Bladder / surgery. Urologic Surgical Procedures / adverse effects


54. Shabbir M, Ryten M, Thompson C, Mikhailidis D, Burnstock G: Purinergic receptor-mediated effects of ATP in high-grade bladder cancer. BJU Int; 2008 Jan;101(1):106-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Purinergic receptor-mediated effects of ATP in high-grade bladder cancer.
  • OBJECTIVE: To assess whether the antineoplastic action of extracellular ATP seen in hormone-refractory prostate cancer extends to other aggressive urological malignancies by investigating its effect in high-grade bladder cancer cells in vitro and in vivo.
  • MATERIALS AND METHODS: HT-1376 cells (human grade 3 transitional cell carcinoma) were incubated with various purinergic receptor agonists and antagonists and their effects on cell growth was examined in vitro.
  • ATP significantly reduced cell growth in a concentration-dependent manner via the induction of P2 receptor-mediated apoptosis.
  • Pharmacological profiling implicated P2X(5) and/or P2Y(11) receptors in this antineoplastic response, the same receptor subtypes shown to be active in prostate adenocarcinoma, despite the differing cellular origin.
  • CONCLUSIONS: ATP effectively reduces the growth of high-grade bladder cancer cells in vitro and in vivo.
  • [MeSH-major] Adenosine Triphosphate / pharmacology. Antineoplastic Agents / pharmacology. Carcinoma, Transitional Cell / drug therapy. Receptors, Purinergic P2 / drug effects. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Humans. Male. Mice. Mice, Nude. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Risk Factors. Signal Transduction

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17941929.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Purinergic P2; 8L70Q75FXE / Adenosine Triphosphate
  •  go-up   go-down


55. Ben Selma W, Ziadi S, Ben Gacem R, Amara K, Ksiaa F, Hachana M, Trimeche M: Investigation of human papillomavirus in bladder cancer in a series of Tunisian patients. Pathol Res Pract; 2010 Nov 15;206(11):740-3
MedlinePlus Health Information. consumer health - HPV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of human papillomavirus in bladder cancer in a series of Tunisian patients.
  • The association between human papillomavirus (HPV) infection and development of bladder cancer is variable.
  • Furthermore, the prevalence of HPV DNA in bladder carcinoma subtypes varies from study to study.
  • To clarify the impact of HPV infection on the development of bladder carcinoma, we performed a retrospective study on Tunisian patients to determine the status of HPV infection in urothelial carcinoma, squamous cell carcinoma, and adenocarcinoma.
  • A total of 125 formalin-fixed, paraffin-embedded archival tissue specimens of bladder carcinoma were reviewed and classified according to the World Health Organization (WHO) classification of tumors (119 urothelial carcinomas, five squamous carcinomas, and one adenocarcinoma).
  • No evidence of HPV infection was detected by morphological examination and PCR in any case of bladder carcinoma.
  • Our study shows that the anogenital HPVs investigated are not associated with the pathogenesis of bladder cancer in Tunisia; however, the question of whether other subtypes of HPV contribute to bladder carcinogenesis remains to be clarified.
  • [MeSH-major] Adenocarcinoma / virology. Alphapapillomavirus / isolation & purification. Carcinoma, Squamous Cell / virology. Carcinoma, Transitional Cell / virology. Papillomavirus Infections / virology. Urinary Bladder Neoplasms / virology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20674191.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


56. Kim ES, Lee DP, Lee MW, Choi JH, Moon KC, Koh JK: Cutaneous metastasis of uterine papillary serous carcinoma. Am J Dermatopathol; 2005 Oct;27(5):436-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous metastasis of uterine papillary serous carcinoma.
  • Uterine papillary serous carcinoma (UPSC) is an uncommon highly malignant variant of endometrial adenocarcinoma that histologically and clinically resembles papillary serous carcinoma of the ovary.
  • This case demonstrates a very rare case of cutaneous metastasis of uterine papillary serous carcinoma.
  • A 54-year-old Korean female developed multiple pruritic skin nodules on the pubic area 13 months later after diagnosis of uterine papillary serous carcinoma.
  • A biopsy of the skin lesions showed papillary serous carcinoma, compatible with her primary tumor.
  • Without clinical history, it is difficult to distinguish other types of metastatic carcinoma to the skin and primary apocrine carcinoma of the skin from metastatic uterine papillary serous carcinoma.
  • Whereas uterine papillary serous carcinoma only rarely involves the skin, this entity should be included in the differential diagnosis of papillary adenocarcinoma in the skin.
  • [MeSH-minor] Bone Neoplasms / secondary. Carcinoma, Transitional Cell / pathology. Female. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Middle Aged. Neoplasms, Second Primary. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16148416.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Singh A, Kinoshita Y, Rovito PM Jr, Landas S, Silberstein J, Nsouli I, Wang CY, Haas GP: Higher than expected association of clinical prostate and bladder cancers. J Urol; 2005 May;173(5):1526-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Higher than expected association of clinical prostate and bladder cancers.
  • PURPOSE: In this study we evaluated the risk of a second malignancy of the bladder or prostate in patients with a previous diagnosis of prostate cancer (PCa) or urothelial cancer (TCC).
  • CONCLUSIONS: Patients with PCa have higher incidence of bladder cancer and those with bladder cancer have a higher incidence of PCa.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Transitional Cell / epidemiology. Neoplasms, Second Primary / epidemiology. Prostatic Neoplasms / epidemiology. Urinary Bladder Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ReprintIn] J Urol. 2008 May;179(5 Suppl):S2-5 [18405742.001]
  • (PMID = 15821472.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


58. Nishikawa K, Soga N, Kato M, Masui S, Hasegawa Y, Yamada Y, Kise H, Arima K, Sugimura Y: [Case of bladder cancer following adjuvant external beam radiation for prostate cancer]. Hinyokika Kiyo; 2009 Jan;55(1):39-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case of bladder cancer following adjuvant external beam radiation for prostate cancer].
  • A 57-year-old male with a history of right renal cell carcinoma was diagnosed with prostate carcinoma associated with a high PSA level (5.2 ng/ml).
  • Histological examination of the resected prostate specimen obtained by radical prostatectomy revealed well differentiated adenocarcinoma, Gleason score 3 + 3, and pT3aN0M0.
  • Seventeen months later, bladder cancer was diagnosed.
  • Histology findings were urothelial carcinoma in situ, G3, and pTisN0M0.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carcinoma, Transitional Cell / diagnosis. Neoplasm Recurrence, Local. Neoplasms, Second Primary. Prostatic Neoplasms / radiotherapy. Urinary Bladder Neoplasms / diagnosis


59. Yu SL, Hou GL, Zhou FJ, Liu ZW, Han H, Qin ZK, Li YH, Zhang ZL, Yao K: [Clinical outcomes after modified radical cystectomy in the treatment of 188 patients with invasive bladder cancer]. Ai Zheng; 2009 May;28(5):500-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical outcomes after modified radical cystectomy in the treatment of 188 patients with invasive bladder cancer].
  • BACKGROUND AND OBJECTIVE: Radical cystectomy and urinary diversion is universally accepted as the most effective treatment for muscle invasive bladder cancer, but the operation is complicated, time-consuming and causes many complications.
  • This study was to summarize our experience and clinical outcomes of modified radical cystectomy in the treatment of patients with muscle invasive bladder cancer.
  • METHODS: In total 188 patients with invasive bladder cancer treated in the Department of Urology, Sun Yat-sen University Cancer Center from January 2000 to December 2007 with modified radical cystectomy and urinary diversion were analyzed retrospectively.
  • The 5-year and overall survival were 82.5% and 82.8% for patients with organ-confined bladder cancer, 19.0% and 34.3% for patients with extravesical extension of bladder cancer, 82.2% and 79.1% for lymph node-negative patients, and 25.2% and 11.4% for lymph node positive patients.
  • CONCLUSIONS: Modified radical cystectomy and urinary diversion is an effective and safe approach in treating muscle invasive bladder cancer.
  • The efficacy of radical cystectomy is limited for the treatment of patients with extravesical extension of bladder cancer and lymph node positive patients.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Survival Rate. Urinary Diversion

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624878.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


60. Shanks JH, Iczkowski KA: Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics. Histopathology; 2009 Jun;54(7):885-900
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Divergent differentiation in urothelial carcinoma and other bladder cancer subtypes with selected mimics.
  • Conventional urothelial carcinoma accounts for most carcinomas of the urinary tract lining.
  • A variety of unusual architectural patterns of urothelial carcinoma, such as the nested, microcystic and inverted variants, can be mistaken for reactive processes or benign tumours.
  • In addition, urothelial carcinoma has a propensity to demonstrate divergent differentiation with glandular, squamous, small cell neuroendocrine, lymphoepithelioma-like, sarcomatoid or other elements.
  • Pure squamous carcinoma or adenocarcinoma (the latter in particular) can be difficult to distinguish from contiguous or metastatic spread.
  • Molecular genetic evidence has emerged recently supporting a close relationship between urothelial carcinoma and various divergent elements.
  • Sarcomatoid carcinoma and its differential diagnosis with other spindle cell lesions of urinary tract will be covered in a separate review.
  • [MeSH-major] Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / pathology. Adenoma / diagnosis. Adenoma / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / pathology. Cell Differentiation. Cystitis / diagnosis. Cystitis / pathology. Diagnosis, Differential. Giant Cell Tumors / diagnosis. Giant Cell Tumors / pathology. Humans. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / pathology. Neoplasms, Squamous Cell / diagnosis. Neoplasms, Squamous Cell / pathology. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / pathology. Radiation Injuries / diagnosis. Radiation Injuries / pathology. Urothelium / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178589.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 152
  •  go-up   go-down


61. Anunobi CC, Banjo AA, Abdulkareem FB, Daramola AO, Akinde OR, Elesha SO: Bladder cancer in Lagos: a 15 year histopathologic review. Niger Postgrad Med J; 2010 Mar;17(1):40-4
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder cancer in Lagos: a 15 year histopathologic review.
  • OBJECTIVE: To present a 15 year retrospective pathologic study of bladder cancers.
  • The aim is to document histologic pattern, prevalence, sex and age distribution of urinary bladder cancer.
  • MATERIALS AND METHODS: The materials consisted of slides, paraffin embedded tissue blocks and histology request forms of all urinary bladder biopsies received at the Morbid Anatomy department of Lagos University Teaching Hospital Idi-Araba, Lagos from 1991 to 2005.
  • RESULTS: Bladder malignancies comprised 39 (72.2 %) cases of all bladder biopsies and 0.86% of all diagnosed cancers in LUTH.
  • The malignant lesions of the bladder showed a male preponderance with a M:F ratio of 4.6:1.
  • Transitional cell carcinoma was the commonest histological type accounting for 61.5% with a male to female ratio of 5:1 and mean age of 59 years.
  • Squamous cell carcinoma accounted for 20.5% with a M:F ratio of 3:1 and showed a mean age of 47 years.
  • Adenocarcinoma, anaplastic carcinoma and embryonal rhabdomyosarcoma accounted for 5.1%, 5.1% and 7.8% of cases respectively.
  • CONCLUSION: Bladder cancer is not common in Lagos.
  • The histopathologic pattern, prevalence, sex and age distribution of bladder cancer are similar to previous reports from schistosomiasis non endemic regions of Nigeria, Africa and the rest of the world.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20348981.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


62. Blank LE, Koedooder K, van Os R, van de Kar M, van der Veen JH, Koning CC: Results of bladder-conserving treatment, consisting of brachytherapy combined with limited surgery and external beam radiotherapy, for patients with solitary T1-T3 bladder tumors less than 5 cm in diameter. Int J Radiat Oncol Biol Phys; 2007 Oct 1;69(2):454-8
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of bladder-conserving treatment, consisting of brachytherapy combined with limited surgery and external beam radiotherapy, for patients with solitary T1-T3 bladder tumors less than 5 cm in diameter.
  • PURPOSE: To evaluate the long-term, local relapse-free, distant metastasis-free, and overall survival rates in patients with a solitary bladder tumor <5 cm in diameter who were treated with external beam radiotherapy, limited surgery, and brachytherapy.
  • METHODS AND MATERIALS: The results of 122 patients after bladder-saving treatment were analyzed.
  • CONCLUSION: The results of our study have shown that external beam radiotherapy followed by brachytherapy as a bladder-saving treatment for a selected group of patients with bladder cancer yields excellent local tumor control and low toxicity.
  • [MeSH-major] Brachytherapy / methods. Cystectomy. Urinary Bladder Neoplasms / radiotherapy. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Transitional Cell / mortality. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / surgery. Combined Modality Therapy / methods. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Staging. Radiotherapy Dosage. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17560734.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Hiros M, Spahović H, Selimović M, Sadović S: Incidental prostate cancer in patients undergoing radical cystoprostatectomy for bladder cancer. Bosn J Basic Med Sci; 2008 May;8(2):147-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental prostate cancer in patients undergoing radical cystoprostatectomy for bladder cancer.
  • The objective of this work is to verify the incidence of incidental prostate adenocarcinoma in patients who underwent radical cystoprostatectomy for invasive bladder carcinoma.
  • We have retrospectively reviewed patients who underwent radical cystoprostatectomy for infiltrative bladder tumors in period between 2003 and 2007 year, 94 men with bladder cancer underwent radical cystoprostatectomy at Urology Clinic-University of Sarajevo Clinics Centre.
  • We found that 9,57% of cystoprostatectomy specimens in patients with bladder cancer also contained incidental prostate cancer.
  • In conclusion we recommended digital rectal examination (DRE) and prostate-specific antigen (PSA) test as part of the bladder cancer work up and complete removal of the prostate at cystoprostatectomy to prevent residual prostate cancer.


64. Neshati V, Matin MM, Iranshahi M, Bahrami AR, Behravan J, Mollazadeh S, Rassouli FB: Cytotoxicity of vincristine on the 5637 cell line is enhanced by combination with conferone. Z Naturforsch C; 2009 May-Jun;64(5-6):317-22
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytotoxicity of vincristine on the 5637 cell line is enhanced by combination with conferone.
  • Bladder cancer is one of the most common cancers worldwide, with the highest incidence in industrialized countries.
  • There are three major histological subtypes of bladder cancer: transitional cell carcinoma (TCC) (> 90%), squamous cell carcinoma (< 10%) and adenocarcinoma (1-2%).
  • [MeSH-major] Coumarins / pharmacology. Urinary Bladder Neoplasms / pathology. Vincristine / pharmacology
  • [MeSH-minor] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Cell Culture Techniques / methods. Cell Division / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Ferula / chemistry. Humans

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19678531.001).
  • [ISSN] 0939-5075
  • [Journal-full-title] Zeitschrift für Naturforschung. C, Journal of biosciences
  • [ISO-abbreviation] Z. Naturforsch., C, J. Biosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Coumarins; 0 / conferone; 5J49Q6B70F / Vincristine
  •  go-up   go-down


65. International Bladder Cancer Nomogram Consortium, Bochner BH, Kattan MW, Vora KC: Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol; 2006 Aug 20;24(24):3967-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer.
  • PURPOSE: Radical cystectomy and pelvic lymphadenectomy (PLND) remains the standard treatment for localized and regionally advanced invasive bladder cancers.
  • We have constructed an international bladder cancer database from centers of excellence in the management of bladder cancer consisting of patients treated with radical cystectomy and PLND.
  • PATIENTS AND METHODS: Institutional radical cystectomy databases containing detailed information on bladder cancer patients were obtained from 12 centers of excellence worldwide.
  • CONCLUSION: We have developed an international bladder cancer nomogram predicting recurrence risk after radical cystectomy for bladder cancer.
  • The nomogram outperformed prognostic models that use standard pathologic subgroupings and should improve our ability to provide accurate risk assessments to patients after the surgical management of bladder cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / secondary. Cystectomy. Nomograms. Urinary Bladder Neoplasms / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Aug 20;24(24):3819-20 [16864852.001]
  • [ErratumIn] J Clin Oncol. 2007 Apr 10;25(11):1457
  • (PMID = 16864855.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


66. Eissa S, Zohny SF, Zekri AR, El-Zayat TM, Maher AM: Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence. Med Oncol; 2010 Dec;27(4):1286-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence.
  • Development of new methods for bladder cancer detection is required because cystoscopy is invasive, and voided urine cytology (VUC) has low sensitivity.
  • The aim of this study was to evaluate the diagnostic performance of urinary fibronectin and mutant p53 in comparison with VUC in the detection of bladder cancer.
  • This study included 100 patients diagnosed with bladder cancer, 93 patients with benign urological disorders and 47 healthy volunteers.
  • Our results indicate that fibronectin had the highest sensitivity compared to VUC and mutant p53 in bladder cancer detection; however, mutant p53 had superior specificity compared to VUC and fibronectin.
  • Mutant p53 is associated with disease recurrence and hence it has a significant prognostic role in bladder cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Transitional Cell / diagnosis. Fibronectins / urine. Mutation / genetics. Tumor Suppressor Protein p53 / genetics. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Animals. Biomarkers, Tumor / genetics. Biomarkers, Tumor / urine. Case-Control Studies. Cystoscopy. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / urine. Neoplasm Staging. Polymerase Chain Reaction. Prognosis. ROC Curve. Schistosoma mansoni / pathogenicity. Schistosomiasis / diagnosis. Schistosomiasis / genetics. Schistosomiasis / urine. Sensitivity and Specificity. Survival Rate. Urinary Bladder / metabolism. Urinary Bladder / pathology

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20012564.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Fibronectins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


67. Quek ML, Nichols PW, Yamzon J, Daneshmand S, Miranda G, Cai J, Groshen S, Stein JP, Skinner DG: Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol; 2005 Jul;174(1):93-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience.
  • PURPOSE: Primary neuroendocrine tumors of the bladder are rare and they include small and large cell variants.
  • MATERIALS AND METHODS: From August 1971 to June 2004, 2,005 patients underwent radical cystectomy for primary bladder cancer at our institution, of whom 25 (1.2%) had neuroendocrine tumors of the bladder, including small cell carcinoma in 20 and large cell carcinoma in 5.
  • Pure neuroendocrine-type histology was identified in 16 cases, including 1 with small and large cell features, while the remaining 9 had mixed histology, that is transitional cell carcinoma in 8 and adenocarcinoma in 1.
  • These tumors tended to have a flat, ulcerative gross appearance with lymphovascular invasion, carcinoma in situ and necrosis present microscopically.
  • There was no significant survival difference between small and large cell carcinoma.
  • CONCLUSIONS: Neuroendocrine tumors of the bladder usually present with advanced pathological stage and portend a poor prognosis.
  • [MeSH-major] Cystectomy / methods. Neuroendocrine Tumors / surgery. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15947585.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Chuang AY, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI: Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol; 2007 Aug;31(8):1246-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
  • In summary, PSA can be used as the first screening marker for differentiating high-grade prostate adenocarcinoma from high-grade urothelial carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Carcinoma, Transitional Cell / secondary. Immunoenzyme Techniques / methods. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667550.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


69. Yi SK, Yoder M, Zaner K, Hirsch AE: Palliative radiation therapy of symptomatic recurrent bladder cancer. Pain Physician; 2007 Mar;10(2):285-90
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative radiation therapy of symptomatic recurrent bladder cancer.
  • With regard to bladder cancer there is some evidence of the benefit of palliative RT for the control of urinary symptoms and hematuria; however, there is little evidence for the use of palliative RT for pain associated with locally recurrent bladder cancer.
  • We report a case of locally advanced recurrent bladder cancer which was refractory to medical pain management, and was found to be highly responsive to palliative RT.
  • CASE REPORT: An 80-year-old woman with recurrent bladder cancer and intractable pelvic pain refractory to oral and transdermal pain medications, received palliative pelvic RT to a dose of 50 Gy (5000 cGy) in 25 fractions with complete resolution of pain.
  • The patient was originally found to have dysuria, frequency, and hematuria, secondary to an invasive high grade transitional cell carcinoma of the bladder with an adenocarcinoma component, AJCC pT2b N1 M0 Stage IV, for which she underwent a radical cystectomy, total abdominal hysterectomy, bilateral salpingo-oophorectomy, partial vaginectomy, and ileal conduit reconstruction.
  • CONCLUSIONS: Palliative radiation therapy has been well studied in the setting of bone metastases and treatment of hematuria for locally advanced bladder cancer.
  • There is little data that we are aware of on the use of RT for pain control with patients that have recurrent, locally advanced bladder cancer.
  • RT is an excellent option for pain management in recurrent bladder cancer and should be offered to patients whose pain is not otherwise optimally controlled.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Pain / radiotherapy. Palliative Care / methods. Urinary Bladder Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17387350.001).
  • [ISSN] 1533-3159
  • [Journal-full-title] Pain physician
  • [ISO-abbreviation] Pain Physician
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Attallah AM, Sakr HA, Ismail H, Abdel-Hady el-SK, El-Dosoky I: An office-based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer. BJU Int; 2005 Aug;96(3):334-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An office-based immunodiagnostic assay for detecting urinary nuclear matrix protein 52 in patients with bladder cancer.
  • OBJECTIVE: To report the rapid (5 min) and simple detection of a nuclear matrix protein (NMP) in the urine of patients with bladder cancer, using a newly developed office-based dot-enzyme-linked immunosorbent assay (ELISA).
  • Urine samples from 149 patients with bladder cancer and 72 controls were evaluated using the developed dot-ELISA.
  • RESULTS: The NMP marker was identified in the urine of patients with bladder cancer at 52 kDa (NMP-52) by Western blot.
  • The dot-ELISA detected the urinary NMP-52 marker in 92% of patients with squamous cell carcinoma, 98% with transitional cell carcinoma, and all six of those with adenocarcinoma of the bladder, with a specificity of 94%.
  • CONCLUSION: Detecting the urinary NMP-52 marker using dot-ELISA would be helpful in the rapid diagnosis and follow-up of patients with bladder cancer.
  • [MeSH-major] Biomarkers, Tumor / urine. Nuclear Matrix-Associated Proteins / urine. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16042726.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Matrix-Associated Proteins
  •  go-up   go-down


71. Pouessel D, Huguet H, Iborra F, Rebillard X, Ayuso D, Becht C, Culine S: A pilot study of gemcitabine in combination with oxaliplatin and vinorelbine in patients with metastatic bladder cancer. Anticancer Res; 2010 Nov;30(11):4711-5
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of gemcitabine in combination with oxaliplatin and vinorelbine in patients with metastatic bladder cancer.
  • AIM: To assess the safety and to obtain preliminary data on the efficacy of the three-drug combination chemotherapy with gemcitabine, oxaliplatin and vinorelbine in patients with metastatic bladder cancer.
  • PATIENTS AND METHODS: Patients with metastatic or locally unresectable advanced bladder cancer who had received either no or one previous systemic chemotherapy regimen were eligible.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Transitional Cell / drug therapy. Urinary Bladder Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21115929.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


72. Kim SY, Oh YL, Kim KM, Jeong EG, Kim MS, Yoo NJ, Lee SH: Decreased expression of Bax-interacting factor-1 (Bif-1) in invasive urinary bladder and gallbladder cancers. Pathology; 2008 Oct;40(6):553-7
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of Bax-interacting factor-1 (Bif-1) in invasive urinary bladder and gallbladder cancers.
  • The aim of this study was to explore whether loss of Bif-1 expression occurs in urinary bladder (UB) and gallbladder (GB) cancer tissues.
  • METHODS: We analysed Bif-1 protein expression in 41 transitional cell carcinomas of UB and 26 GB adenocarcinomas by immunohistochemistry.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / biosynthesis. Adenocarcinoma / metabolism. Carcinoma, Transitional Cell / metabolism. Gallbladder Neoplasms / metabolism. Urinary Bladder Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18752120.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / SH3GLB1 protein, human
  •  go-up   go-down


73. Numata K, Azuma K, Hashine K, Sumiyoshi Y: [Two cases of second bladder cancer after radiotherapy for prostate cancer]. Nihon Hinyokika Gakkai Zasshi; 2005 Mar;96(3):466-9
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of second bladder cancer after radiotherapy for prostate cancer].
  • We report two cases of second bladder cancer after radiotherapy for prostate cancer.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carcinoma, Transitional Cell / etiology. Neoplasms, Second Primary / etiology. Prostatic Neoplasms / radiotherapy. Radiotherapy / adverse effects. Urinary Bladder Neoplasms / etiology


74. Kaya K, Ayan S, Gokce G, Kilicarslan H, Yildiz E, Gultekin EY: Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma. Scand J Urol Nephrol; 2005;39(1):25-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma.
  • OBJECTIVE: To determine the incidence of positive urinary nuclear matrix protein 22 (NMP22) values, which are currently used to detect transitional cell carcinoma of the bladder, in renal cell carcinoma (RCC).
  • Two patients had xanthogranulomatous pyelonephritis and one had metastasis of a small cell adenocarcinoma to the kidney; these patients were excluded from the study.
  • As elevated urinary NMP22 levels have also been found to occur in RCC, patients with suspected bladder cancer and positive urinary NMP22 levels should be more broadly evaluated.
  • [MeSH-major] Biomarkers, Tumor / urine. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Nuclear Proteins / urine

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764267.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Reagent Kits, Diagnostic; 0 / nuclear matrix protein 22
  •  go-up   go-down


75. Knottenbelt C, Mellor D, Nixon C, Thompson H, Argyle DJ: Cohort study of COX-1 and COX-2 expression in canine rectal and bladder tumours. J Small Anim Pract; 2006 Apr;47(4):196-200
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cohort study of COX-1 and COX-2 expression in canine rectal and bladder tumours.
  • OBJECTIVES: To determine the role that cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) play in malignant transformation in canine transitional cell carcinoma and rectal tumours.
  • METHODS: Histological sections of 21 canine rectal adenocarcinomas and 18 canine transitional cell carcinomas were stained for COX-1 and COX-2.
  • For transitional cell carcinomas, all of the sections were positive for COX-1 and COX-2.
  • CLINICAL SIGNIFICANCE: The variations in COX expression reported in this study may explain the differences in the clinical response of transitional cell carcinomas and rectal adenocarcinomas following treatment with non-steroidal anti-inflammatory drugs.
  • [MeSH-major] Adenocarcinoma / veterinary. Carcinoma, Transitional Cell / veterinary. Dog Diseases / enzymology. Prostaglandin-Endoperoxide Synthases / genetics. Rectal Neoplasms / veterinary. Urinary Bladder Neoplasms / veterinary
  • [MeSH-minor] Age Factors. Animals. Cell Transformation, Neoplastic. Cohort Studies. Cyclooxygenase 1 / genetics. Cyclooxygenase 1 / metabolism. Cyclooxygenase 2 / genetics. Cyclooxygenase 2 / metabolism. Dogs. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Immunohistochemistry. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16573762.001).
  • [ISSN] 0022-4510
  • [Journal-full-title] The Journal of small animal practice
  • [ISO-abbreviation] J Small Anim Pract
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


76. Khaled H, Emara ME, Gaafar RM, Mansour O, Abdel Warith A, Zaghloul MS, El Malt O: Primary chemotherapy with low-dose prolonged infusion gemcitabine and cisplatin in patients with bladder cancer: a Phase II trial. Urol Oncol; 2008 Mar-Apr;26(2):133-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chemotherapy with low-dose prolonged infusion gemcitabine and cisplatin in patients with bladder cancer: a Phase II trial.
  • BACKGROUND: Gemcitabine is an active agent in the treatment of bladder cancer.
  • PATIENTS AND METHODS: Based on previously published Phase I trials, the efficacy and safety of a combination of cisplatin and gemcitabine given as prolonged infusion were tried in a Phase II study of 57 untreated patients with stage III/IV bladder cancer, which is the most common malignant tumor among Egyptian males.
  • A total of 37 patients had transitional cell, 15 had squamous cell, 2 had adenocarcinoma, and 3 had undifferentiated cell carcinoma.
  • CONCLUSIONS: Prolonged infusion of gemcitabine and cisplatin is an effective treatment for advanced bilharzial-related bladder cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cisplatin / administration & dosage. Deoxycytidine / analogs & derivatives. Urinary Bladder Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312930.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


77. Siefker-Radtke A: Urachal carcinoma: surgical and chemotherapeutic options. Expert Rev Anticancer Ther; 2006 Dec;6(12):1715-21
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urachal carcinoma: surgical and chemotherapeutic options.
  • The urachal ligament is an embryologic remnant connecting the dome of the bladder to the umbilicus via the ligamentum commune.
  • Patients usually present with hematuria and upon imaging, have evidence of a cystic or solid structure in the bladder dome or in the bladder midline.
  • If a biopsy confirms adenocarcinoma, these tumors should be considered an urachal cancer until proven otherwise.
  • [MeSH-major] Adenocarcinoma / therapy. Cystectomy / methods. Urachus / pathology. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / pathology. Cisplatin / administration & dosage. Clinical Trials as Topic. Clinical Trials, Phase II as Topic. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Diagnosis, Differential. Female. Fluorouracil / administration & dosage. Hematuria / etiology. Humans. Leucovorin / administration & dosage. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Risk Factors. Umbilicus / surgery. Urachal Cyst / pathology. Urachal Cyst / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17181485.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Number-of-references] 29
  •  go-up   go-down


78. Abdel Wahab AH, Abo-Zeid HI, El-Husseini MI, Ismail M, El-Khor AM: Role of loss of heterozygosity on chromosomes 8 and 9 in the development and progression of cancer bladder. J Egypt Natl Canc Inst; 2005 Dec;17(4):260-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of loss of heterozygosity on chromosomes 8 and 9 in the development and progression of cancer bladder.
  • Non-random chromosome deletion and LOH at specific chromosomal regions are identified in a number of common human cancers including carcinoma of the bladder, which is considered the most predominant cancer in Egypt due to the prevalence of schistosomiasis.
  • PURPOSE: The main objective of the present study is to clarify the role of chromosomes 8 and 9 in the establishment and/or progression of schistosomiasis-related bladder cancer through detection of LOH of 8 microsatellite markers on both chromosomes.
  • It also aims to compare the LOH pattern of the tested markers between schistosomiasis- associated and non schistosomiasis-associated bladder cancer.
  • MATERIAL AND METHODS: To achieve this purpose, DNA was extracted from the tumor specimens and the corresponding peripheral blood samples of 42 primary bladder cancer patients (schistosomal and non schistosomal).
  • Twenty nine of these were diagnosed as squamous cell type (SCC), 11 were transitional (TCC), and 2 were adenocarcinoma (with different stages and grades).
  • Fifty nine percent (59%) of the cases with LOH at 9q were diagnosed as squamous cell type (SCC), whereas 9% only were transitional cell type (TCC).
  • CONCLUSION: Our data indicate that more than one tumor suppressor gene on chromosomes 8 and 9 are involved in high grades of bladder carcinogenesis, one at 8p12 and another at 8q21.1 regions.
  • Also, a region at 8q23-quarter may harbor tumor suppressor gene that involved in metastasis of bladder cancer.
  • PTCH located at 9q22.3, as well as the TSC gene at 9q34 are involved in squamous cell carcinoma rather than transitional carcinoma.
  • Finally, the present study shows no line of demarcation between schistosomiasis-associate and non schistosomiasis-associated bladder cancer in terms of LOH of the tested microsatellite markers on chromosome 8 and 9.
  • This suggests that data obtained from schistosoma-associated bladder cancer can be extrapolated to bladder cancer induced by a schistosomiasis independent mechanism.
  • [MeSH-major] Chromosomes, Human, Pair 8 / genetics. Chromosomes, Human, Pair 9 / genetics. Loss of Heterozygosity. Schistosomiasis haematobia / complications. Urinary Bladder Neoplasms / genetics

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17102820.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


79. Hisamatsu H, Yamashita S: [A case of metastatic lung cancer with cavitation due to urothelial carcinoma]. Hinyokika Kiyo; 2010 May;56(5):269-72
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastatic lung cancer with cavitation due to urothelial carcinoma].
  • We report a rare case of lung cancer with cavitation that was caused by metastasis of urothelial carcinoma.
  • Subsequently, transurethral resection was performed several times for bladder tumor.
  • On the basis of the pathological findings, we diagnosed the mass as metastatic tumor secondary to the urothelial carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / radiography. Carcinoma, Transitional Cell / secondary. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Ureteral Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Female. Humans. Nephrectomy. Sigmoid Neoplasms / pathology. Tomography, X-Ray Computed. Ureter / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20519925.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


80. Nese N, Kesici G, Lekili M, Isisag A: Urachal urothelial carcinoma diagnosed at a radical prostatectomy operation: a case report. Anal Quant Cytol Histol; 2010 Jun;32(3):174-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urachal urothelial carcinoma diagnosed at a radical prostatectomy operation: a case report.
  • Prostatic adenocarcinoma (PCa) (Gleason score 6) was diagnosed by needle biopsies.
  • After the diagnosis of high grade, muscle invasive UCa with intact mucosa on frozen examination of the dome of bladder wall during the radical prostatectomy operation (RPO), partial cystectomy was performed.
  • Six months after the diagnosis, an undifferentiated tumor was detected in a bladder transurethral resection specimen; thus, chemotherapy was given.
  • CONCLUSION: The origin of urachal carcinomas is usually obscured as it is a highly invasive carcinoma.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701072.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Waalkes MP, Liu J, Ward JM, Diwan BA: Enhanced urinary bladder and liver carcinogenesis in male CD1 mice exposed to transplacental inorganic arsenic and postnatal diethylstilbestrol or tamoxifen. Toxicol Appl Pharmacol; 2006 Sep 15;215(3):295-305
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced urinary bladder and liver carcinogenesis in male CD1 mice exposed to transplacental inorganic arsenic and postnatal diethylstilbestrol or tamoxifen.
  • Arsenic alone increased hepatocellular carcinoma (14%), adenoma (23%) and total tumors (31%) compared to control (0, 2 and 2%, respectively).
  • Arsenic alone also increased lung adenocarcinoma, adrenal cortical adenoma and renal cystic tubular hyperplasia compared to control.
  • The treatments alone did not impact urinary bladder carcinogenesis, but arsenic plus TAM significantly increased formation of urinary bladder transitional cell tumors (papilloma and carcinoma; 13%) compared to control (0%).
  • Urinary bladder proliferative lesions (combined tumors and hyperplasia) were also increased by arsenic plus TAM (40%) or arsenic plus DES (43%) compared to control (0%) or the treatments alone.
  • Urinary bladder proliferative lesions occurred in the absence of any evidence of uroepithelial cytotoxic lesions.
  • Urinary bladder lesions and hepatocellular carcinoma induced by arsenic plus TAM and/or DES overexpressed estrogen receptor-alpha, indicating that aberrant estrogen signaling may have been a factor in the enhanced carcinogenic response.
  • Thus, in male CD1 mice, gestational arsenic exposure alone induced liver adenoma and carcinoma, lung adenocarcinoma, adrenal adenoma and renal cystic hyperplasia.
  • In utero arsenic also initiated urinary bladder tumor formation when followed by postnatal TAM and uroepithelial proliferative lesions when followed by TAM or DES.
  • [MeSH-major] Arsenic / toxicity. Diethylstilbestrol / toxicity. Liver Neoplasms / etiology. Tamoxifen / toxicity. Urinary Bladder Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16712894.001).
  • [ISSN] 0041-008X
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-12400; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogens, Non-Steroidal; 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen; 731DCA35BT / Diethylstilbestrol; N712M78A8G / Arsenic
  •  go-up   go-down


82. Røtterud R, Fosså SD, Nesland JM: Protein networking in bladder cancer: immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium. Histol Histopathol; 2007 04;22(4):349-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein networking in bladder cancer: immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium.
  • A panel of markers, selected for the suspected bladder cancer relevance of their corresponding genes, were explored for their expression and subcellular location in urinary bladder tissue.
  • The expression in normal urothelium, in non-metastasised transitional cell carcinomas (TCC), and in primary metastasised TCC with corresponding metastases was mapped.
  • Membranous ERBB4 and cytoplasmic p21RAS were downregulated in carcinoma cells compared with normal urothelium cells.
  • According to our results, bladder carcinogenesis comprises FGFR3 translocation to the nucleus, upregulation of EGFR, ERBB2, KAI1 and PTEN; downregulation of p21RAS; and translocation of EGFR, ERBB2, and possibly PTEN to the membrane.
  • Our results support the hypotheses regarding PTEN and KAI1 functioning as tumour suppressors in bladder cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Neoplasm Proteins / metabolism. Urinary Bladder Neoplasms / metabolism. Urothelium / metabolism

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290345.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antigens, CD82; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.1.3.67 / PTEN protein, human; EC 3.6.5.2 / Oncogene Protein p21(ras)
  •  go-up   go-down


83. Canjuga I, Mravak-Stipetić M, Kopić V, Galić J: Oral acanthosis nigricans: case report and comparison with literature reports. Acta Dermatovenerol Croat; 2008;16(2):91-5
MedlinePlus Health Information. consumer health - Mouth Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant AN is most often associated with gastric adenocarcinoma but cancers of other sites and types may also occur.
  • This case report is based on a case of a 78-year-old woman suffering from invasive bladder papillary transitional cell carcinoma accompanied by extensive papillomatous areas of normal mucosal color and soft consistency involving the lips, buccal mucosa and hard palate.
  • [MeSH-major] Acanthosis Nigricans / etiology. Acanthosis Nigricans / pathology. Carcinoma, Transitional Cell / complications. Mouth Diseases / etiology. Mouth Diseases / pathology. Urinary Bladder Neoplasms / complications

  • Genetic Alliance. consumer health - Acanthosis Nigricans.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541106.001).
  • [ISSN] 1330-027X
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Croatia
  • [Number-of-references] 20
  •  go-up   go-down


84. Hirata K, Kanemitsu S, Nakayama Y, Nagata N, Itoh H, Ohnishi H, Ishikawa H, Furukawa Y, HNPCC registry and genetic testing project of the Japanese Society for Cancer of the Colon and Rectum (JSCCR): A novel germline mutation of MSH2 in a hereditary nonpolyposis colorectal cancer patient with liposarcoma. Am J Gastroenterol; 2006 Jan;101(1):193-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: A 40-yr-old Japanese patient, who had a past history of adenocarcinoma of the rectum and transitional cell carcinoma of the urinary bladder, developed a liposarcoma in his left thigh.
  • [MeSH-major] Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Liposarcoma / pathology. Muscle Neoplasms / pathology. MutS Homolog 2 Protein / genetics. Neoplasms, Multiple Primary / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Base Pair Mismatch. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / pathology. Follow-Up Studies. Germ-Line Mutation. Humans. Male. Risk Assessment


85. Bryan JN, Keeler MR, Henry CJ, Bryan ME, Hahn AW, Caldwell CW: A population study of neutering status as a risk factor for canine prostate cancer. Prostate; 2007 Aug 1;67(11):1174-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Veterinary Medical Databases (VMDB) were queried to yield male dogs with urinary bladder transitional cell carcinoma (TCC), prostate adenocarcinoma (ACA), prostate TCC, prostate carcinoma (CA), and prostate tumors.
  • Neutered males had an odds ratio of 3.56 (3.02-4.21) for urinary bladder TCC, 8.00 (5.60-11.42) for prostate TCC, 2.12 (1.80-2.49) for prostate adenocarcinoma, 3.86 (3.13-4.16) for prostate carcinoma, and 2.84 (2.57-3.14) for all prostate cancers.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / veterinary. Animals. Carcinoma / epidemiology. Carcinoma / veterinary. Carcinoma, Transitional Cell / epidemiology. Carcinoma, Transitional Cell / veterinary. Dogs. Genetic Predisposition to Disease. Male. Odds Ratio. Risk Factors. Species Specificity. Urinary Bladder Neoplasms / epidemiology. Urinary Bladder Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17516571.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Grant] United States / NLM NIH HHS / LM / T15-LM07089
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


86. Hu F, Hu XH, Yu P, Zhang JX, Lou GG, Liu HL, Wu B, Zhao RH, Xia HQ, Wang Y, Chen J, Ben Y, Chen SY: [Abscopal effect on metastatic tumor induced by oncolytic virus of H101 combining with local heating]. Ai Zheng; 2006 Aug;25(8):919-24
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Five patients with histologically confirmed, surgically unresectable metastatic malignant tumors (2 nasopharyngeal carcinomas, 1 pulmonary carcinoma, 1 parosteal sarcoma and 1 bladder carcinoma) that had definitely failed to the conventional chemotherapy and radiotherapy or refused these therapies were enrolled in this experimental therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy. Hyperthermia, Induced. Oncolytic Virotherapy. Oncolytic Viruses / physiology
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Adenoviridae / genetics. Adenoviridae / physiology. Aged. Carcinoma, Transitional Cell / secondary. Carcinoma, Transitional Cell / therapy. Female. Follow-Up Studies. Humans. Injections, Intralesional. Lung Neoplasms / pathology. Lung Neoplasms / therapy. Lymphatic Metastasis. Male. Middle Aged. Nasopharyngeal Neoplasms / pathology. Nasopharyngeal Neoplasms / therapy. Treatment Outcome. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / therapy. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965669.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


87. Popov Z, Stavridis A, Lekovski Lj, Penev M, Dohcev S, Stankov O, Petrovski D, Saidi S, Kuzmanoski M, Stavridis S, Mickovski A, Banev S, Zografski G, Janculev J, Ivanovski O, Georgiev V: Urinary diversion: 30 years experience of a single centre in Republic of Macedonia. Acta Chir Iugosl; 2007;54(4):49-55

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The aim of this report is to present our 30 years experience with various types of urinary diversions, in particular the Bricker and Studer techniques for the management of muscle invasive bladder cancer at our institution.
  • Histopathologically, transitional cell carcinoma was the most common tumor cell type (93,7%), followed by difuse papilomatosis (5.5%) and adenocarcinoma (0.7%).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Cystectomy. Female. Humans. Male. Middle Aged. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery. Urinary Reservoirs, Continent

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18595229.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


88. Saad M, Abdel-Rahim M, Abol-Enein H, Ghoneim MA: Concomitant pathology in the prostate in cystoprostatectomy specimens: a prospective study and review. BJU Int; 2008 Dec;102(11):1544-50
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To investigate possible associated pathology in the prostate removed from patients with invasive bladder cancer and determine if there is a justification for prostate-sparing cystectomy.
  • RESULTS: Prostatic adenocarcinoma was detected in 90 of the 425 (21.2%) patients.
  • There was no significant correlation between preoperative prostate-specific antigen level and the presence of adenocarcinoma, Gleason score or prostatic tumour stage.
  • There was prostatic involvement as a result of direct invasion by the primary bladder tumour (contiguous) in 39 cases (9.2%).
  • Concomitant (non-contiguous) transitional cell carcinoma of the prostatic urethra and/or ducts was detected in 27 specimens (6.4%).
  • [MeSH-major] Cystectomy / methods. Prostate / pathology. Prostatectomy / methods. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prospective Studies. Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / surgery. Prostatic Intraepithelial Neoplasia / pathology. Prostatic Intraepithelial Neoplasia / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565169.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 65
  •  go-up   go-down


89. Pearce A, Reid C, Gramp A, Sidhu S: A 30-year history of CD4+ vesiculo-bullous mycosis fungoides and multiple visceral malignancies. Australas J Dermatol; 2007 Feb;48(1):46-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She had a past history of adenocarcinoma of the lung, colorectal carcinoma and bladder carcinoma.
  • The literature on this rare phenotype of cutaneous T-cell lymphoma generally portrays a negative prognosis.
  • [MeSH-minor] Adenocarcinoma / complications. Administration, Cutaneous. Aged. Aged, 80 and over. Betamethasone / analogs & derivatives. Betamethasone / therapeutic use. Carcinoma, Transitional Cell / complications. Colorectal Neoplasms / complications. Diagnosis, Differential. Female. Humans. Lung Neoplasms / complications. Urinary Bladder Neoplasms / complications

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BETAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222304.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD4; 826Y60901U / betamethasone-17,21-dipropionate; 9842X06Q6M / Betamethasone
  •  go-up   go-down


90. Glatt S, Halbauer D, Heindl S, Wernitznig A, Kozina D, Su KC, Puri C, Garin-Chesa P, Sommergruber W: hGPR87 contributes to viability of human tumor cells. Int J Cancer; 2008 May 1;122(9):2008-16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report the contribution of hGPR87, a predicted member of the P2Y subfamily of GPCRs, to proliferation and survival of human tumor cell lines. hGPR87 mRNA transcript was found to be preferentially overexpressed in squamous cell carcinomas (SCCs) of different locations and in their lymph node metastases.
  • In addition to the expression of hGPR87 in tumors which originate from stratified epithelia, we identified other hGPR87-positive tumor types including subsets of large cell and adenocarcinomas of the lung and transitional cell carcinomas of the urinary bladder.
  • Loss of function studies using siRNA in human cancer cell lines lead to antiproliferative effects and induction of apoptosis.
  • Like other known P2Y receptors, hGPR87 was found to be mainly located on the cell surface.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Neoplasms / metabolism. Receptors, Lysophosphatidic Acid / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Apoptosis. Carcinoma, Large Cell / metabolism. Carcinoma, Transitional Cell / metabolism. Cell Line, Tumor. Cell Proliferation. Cell Survival. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Head and Neck Neoplasms / metabolism. Humans. Immunoblotting. Immunohistochemistry. Lung Neoplasms / metabolism. Male. Polymerase Chain Reaction. RNA, Small Interfering / metabolism. Skin Neoplasms / metabolism. Transcription, Genetic. Up-Regulation. Urinary Bladder Neoplasms / metabolism. Uterine Cervical Neoplasms / metabolism

  • Guide to Pharmacology. gene/protein/disease-specific - GPR87 - data and references .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18183596.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPR87 protein, human; 0 / RNA, Small Interfering; 0 / Receptors, Lysophosphatidic Acid
  •  go-up   go-down


91. Sanli O, Acar O, Celtik M, Oktar T, Kilicaraslan I, Ozcan F, Tunc M, Esen T: Should prostate cancer status be determined in patients undergoing radical cystoprostatectomy? Urol Int; 2006;77(4):307-10
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: A total of 97 radical cystoprostatectomies without evidence of prostate cancer on digital rectal examination were performed for transitional cell carcinomas of the bladder between January 2001 and May 2004.
  • CONCLUSIONS: Despite the high prevalence of incidental prostate carcinomas among patients with bladder cancer undergoing cystoprostatectomy, the vast majority of the cancers are organ confined.
  • [MeSH-major] Adenocarcinoma / pathology. Cystectomy. Prostatectomy. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Diagnosis, Differential. Follow-Up Studies. Humans. Incidence. Intraoperative Period. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17135779.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


92. Sanghera P, Ho K, Muscroft T, Hartley A: Neoadjuvant chemotherapy enables R0 resection of locally advanced rectal cancer in a patient with a previously irradiated pelvis. Br J Radiol; 2007 Aug;80(956):e170-2
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a case where radiotherapy was contraindicated as the patient had previously been irradiated to a radical dose for prostatic adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Aged. Capecitabine. Carcinoma, Transitional Cell / radiotherapy. Colonic Pouches. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Magnetic Resonance Imaging. Male. Organoplatinum Compounds / administration & dosage. Prostatic Neoplasms / radiotherapy. Urinary Bladder Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17762049.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


93. Pagano S, Ruggeri P, Rovellini P, Bottanelli A: The anterior ileal conduit: results of 100 consecutive cases. J Urol; 2005 Sep;174(3):959-62; discussion 962
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The ileal conduit of Bricker is still widely used for urinary diversion after radical cystectomy for bladder carcinoma.
  • RESULTS: A total of 100 consecutive patients after radical cystectomy for bladder cancer had anterior ileal conduit.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / surgery. Cystectomy. Postoperative Complications / etiology. Urinary Bladder Neoplasms / surgery. Urinary Diversion / methods

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094008.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Mhawech P, Greloz V, Assaly M, Herrmann F: Immunohistochemical expression of 14-3-3 sigma protein in human urological and gynecological tumors using a multi-tumor microarray analysis. Pathol Int; 2005 Feb;55(2):77-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most frequent expression was seen in squamous cell carcinoma of the cervix and urothelial bladder carcinoma, followed by prostatic and endometrial adenocarcinoma.
  • 14-3-3 sigma was able to distinguish prostate adenocarcinoma from urothelial bladder carcinoma, with an odds ratio of 0.028 (P = 0.001; 95% CI, 0.0003-0.222), and distinguish seminoma from embryonal carcinoma of the testis, with an odds ratio of 0.061 (P = 0.009; 95% CI, 0.007-0.5014).
  • It also has a good value in differentiating renal clear cell carcinoma from papillary carcinoma, with an odds ratio 0.470 (P < 0.001; 95% CI, 0.008-0.261).
  • [MeSH-minor] 14-3-3 Proteins. Adenocarcinoma / diagnosis. Carcinoma, Embryonal / diagnosis. Carcinoma, Transitional Cell / diagnosis. Diagnosis, Differential. Exoribonucleases. Female. Humans. Male. Odds Ratio. Prostatic Neoplasms / diagnosis. Seminoma / diagnosis. Testicular Neoplasms / diagnosis. Urologic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693853.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human
  •  go-up   go-down


95. di Capua Sacoto C, Luján Marco S, Bahilo Mateu P, Budía Alba A, Pontones Moreno JL, Jiménez Cruz JF: [De novo urological neoplasms in kidney transplant patients: experience in 1,751 patients]. Actas Urol Esp; 2010 Jan;34(1):88-94
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [De novo urological neoplasms in kidney transplant patients: experience in 1,751 patients].
  • [Transliterated title] Neoplasias urológicas de novo en pacientes trasplantados renales: experiencia en 1.751 pacientes.
  • OBJECTIVE: To perform a descriptive analysis of de novo urological tumors in kidney transplant patients and to analyze patient survival.
  • RESULTS: Twenty-nine de novo tumors (1.6%) were diagnosed in the 1751 transplanted patients, with a median follow-up of 35.28 months (2-121) from tumor diagnosis.
  • Eleven patients (38%) were diagnosed with prostate cancer, seven (24%) with bladder tumors, 4 (60%) with non-muscle invasive tumors, and 3 (40%) with muscle invasive tumors.
  • A renal adenocarcinoma in the primitive kidney was diagnosed in 6 patients (20%).
  • Median survival was 75 months for patients with bladder tumors, 82 months for prostate cancer, 59 months for tumors in the native kidney, and 86 months for graft tumors.
  • CONCLUSIONS: In our series, de novo urological tumors in kidney transplant recipients were more common in males.
  • Prostate cancer is the most common tumor and renal cell carcinoma of the native kidney has the worst survival rate.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / immunology. Adult. Aged. Carcinoma, Transitional Cell / epidemiology. Carcinoma, Transitional Cell / immunology. Disease Susceptibility. Female. Humans. Immunocompromised Host. Immunosuppression / adverse effects. Kaplan-Meier Estimate. Kidney Neoplasms / epidemiology. Kidney Neoplasms / immunology. Male. Middle Aged. Prostatic Neoplasms / epidemiology. Prostatic Neoplasms / immunology. Retrospective Studies. Sex Distribution. Spain / epidemiology. Urinary Bladder Neoplasms / epidemiology. Urinary Bladder Neoplasms / immunology. Young Adult

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223138.001).
  • [ISSN] 1699-7980
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


96. Kaouk JH, Goel RK, White MA, White WM, Autorino R, Haber GP, Campbell SC: Laparoendoscopic single-site radical cystectomy and pelvic lymph node dissection: initial experience and 2-year follow-up. Urology; 2010 Oct;76(4):857-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The eligible patients had transitional cell carcinoma that was muscle invasive or refractory to intravesical therapy.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Endoscopy / methods. Laparoscopy / methods. Lymph Node Excision / methods. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Equipment Design. Feasibility Studies. Female. Follow-Up Studies. Humans. Laparoscopes. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Pelvis. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery. Urinary Diversion

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20646750.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Weidle UH, Evtimova V, Alberti S, Guerra E, Fersis N, Kaul S: Cell growth stimulation by CRASH, an asparaginase-like protein overexpressed in human tumors and metastatic breast cancers. Anticancer Res; 2009 Apr;29(4):951-63
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell growth stimulation by CRASH, an asparaginase-like protein overexpressed in human tumors and metastatic breast cancers.
  • On the other hand, 36/50 ovarian carcinomas, 16/78 mammary carcinomas, 6/6 uroepithelial bladder carcinomas and 5/33 colon carcinomas scored positive for CRASH, with the absence of reactivity in the corresponding normal tissues.
  • The somatic knock-out of CRASH resulted in significant inhibition of growth of KM12L4A colon carcinoma cells, which abundantly express CRASH, whereas the proliferation of the syngeneic, weakly-expressing, slowly-growing KL12SM was not affected.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Amino Acid Sequence. Animals. Antibodies, Monoclonal / immunology. Blotting, Western. Carcinoma, Transitional Cell / metabolism. Carcinoma, Transitional Cell / secondary. Cell Line, Tumor. Cystadenocarcinoma / metabolism. Cystadenocarcinoma / secondary. Female. Humans. Immunoenzyme Techniques. Mice. Mice, Inbred BALB C. Molecular Sequence Data. Prognosis. RNA, Small Interfering / pharmacology. Sequence Homology, Amino Acid

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414332.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Autoantigens; 0 / RNA, Small Interfering; EC 3.5.1.- / ASRGL1 protein, human; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


98. Rozet F, Lesur G, Cathelineau X, Barret E, Smyth G, Soon S, Vallancien G: Oncological evaluation of prostate sparing cystectomy: the Montsouris long-term results. J Urol; 2008 Jun;179(6):2170-4; discussion 2174-5
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Prostate sparing cystectomy provides an alternative therapeutic option in highly selected patients with invasive bladder cancer who wish to avoid the significant functional side effects of traditional surgery.
  • Concern exists regarding the oncological safety of this technique especially with regard to the presence of prostatic urothelial cancer and incidental prostate adenocarcinoma.
  • RESULTS: Nine patients underwent radical cystoprostatectomy after prostate urothelial carcinoma was diagnosed intraoperatively.
  • Of 6 patients found to have prostate adenocarcinoma in transurethral prostate resection specimens 1 was treated with high intensity focused ultrasound and 5 were followed with active surveillance, 2 of whom later died of bladder cancer.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18423740.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Al-Mufarrej F, Kamel MH, Mohan P, Hickey D: Tricorporal priapism postradical cystoprostatectomy: first sign of recurrent urogenital malignancy. Int J Urol; 2006 Apr;13(4):460-2
Genetic Alliance. consumer health - Priapism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of proximal tricorporal priapism, secondary to penile metastasis of a bladder malignancy postradical cystoprostatectomy.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16734875.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


100. Wolk M, Martin JE, Reinus C: Development of fetal haemoglobin-blood cells (F cells) within colorectal tumour tissues. J Clin Pathol; 2006 Jun;59(6):598-602
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Immunoaffinity-purified anti-HbF was immunohistochemically used to study F cell distribution in the following cancers: colorectal adenocarcinoma, urinary bladder transitional cell carcinoma, brain tumours, lung carcinoma, breast adenocarcinoma, leukaemia, Burkitt's lymphoma and endometrial carcinoma.
  • RESULTS: In colorectal adenocarcinoma, HbF-containing red blood cells (FRBC) were present within thin-walled vessels or were disposed in dense clusters within the tumour.
  • In half of the cases with transitional cell carcinoma of the urinary bladder, regional intratumoral blood vessels were found to contain 5-50% FRBC.
  • [MeSH-major] Adenocarcinoma / blood supply. Colorectal Neoplasms / blood supply. Fetal Hemoglobin / metabolism. Neovascularization, Pathologic / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Brain Neoplasms / blood supply. Breast Neoplasms / blood supply. Erythroblasts / metabolism. Female. Humans. Leukemia / blood. Lung Neoplasms / blood supply. Male. Middle Aged. Urinary Bladder Neoplasms / blood supply

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blut. 1990 Jul;61(1):17-20 [1696840.001]
  • [Cites] Tumour Biol. 1991;12(1):45-51 [1705048.001]
  • [Cites] Blood. 1995 Jul 1;86(1):323-8 [7795240.001]
  • [Cites] Pediatr Res. 1995 Oct;38(4):555-63 [8559609.001]
  • [Cites] Blood. 1996 Jan 15;87(2):557-66 [8555477.001]
  • [Cites] Immunol Today. 1998 May;19(5):228-36 [9613041.001]
  • [Cites] Semin Hematol. 2004 Oct;41(4 Suppl 6):3-10 [15534851.001]
  • [Cites] Development. 1999 Nov;126(22):5073-84 [10529424.001]
  • [Cites] Blood. 2000 May 1;95(9):2967-74 [10779447.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1847-52 [11172039.001]
  • [Cites] Haematologica. 2002 Mar;87(3):323-5 [11869947.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1478-83 [12145688.001]
  • [Cites] Ann Hematol. 2002 Sep;81(9):548-50 [12373361.001]
  • [Cites] Blood. 2003 Jan 15;101(2):492-7 [12393703.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1669-76 [12406884.001]
  • [Cites] Clin Chem Lab Med. 2003 May;41(5):646-51 [12812262.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1929-33 [14592835.001]
  • [Cites] J Clin Pathol. 2004 Jul;57(7):740-5 [15220368.001]
  • [Cites] Ann N Y Acad Sci. 1974 Nov 29;241(0):638-52 [4611309.001]
  • [Cites] Acta Haematol. 1977;58(5):288-93 [74180.001]
  • [Cites] J Pathol. 1981 May;134(1):71-80 [6169819.001]
  • (PMID = 16469830.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9034-63-3 / Fetal Hemoglobin
  • [Other-IDs] NLM/ PMC1860403
  •  go-up   go-down






Advertisement